0001290658 false --12-31 2022 Q3 No No
0001290658 2022-01-01 2022-09-30 0001290658 2022-11-09 0001290658
2022-09-30 0001290658 2021-12-31 0001290658
ITOX:SeriesBConvertiblePreferredStockMember 2022-09-30 0001290658
ITOX:SeriesBConvertiblePreferredStockMember 2021-12-31 0001290658
2022-07-01 2022-09-30 0001290658 2021-07-01 2021-09-30 0001290658
2021-01-01 2021-09-30 0001290658 us-gaap:PreferredStockMember
2022-06-30 0001290658 us-gaap:CommonStockMember 2022-06-30
0001290658 us-gaap:AdditionalPaidInCapitalMember 2022-06-30
0001290658 us-gaap:RetainedEarningsMember 2022-06-30 0001290658
2022-06-30 0001290658 us-gaap:PreferredStockMember 2021-12-31
0001290658 us-gaap:CommonStockMember 2021-12-31 0001290658
us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001290658
us-gaap:RetainedEarningsMember 2021-12-31 0001290658
us-gaap:PreferredStockMember 2021-06-30 0001290658
us-gaap:CommonStockMember 2021-06-30 0001290658
us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001290658
us-gaap:RetainedEarningsMember 2021-06-30 0001290658 2021-06-30
0001290658 us-gaap:PreferredStockMember 2020-12-31 0001290658
us-gaap:CommonStockMember 2020-12-31 0001290658
us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001290658
us-gaap:RetainedEarningsMember 2020-12-31 0001290658 2020-12-31
0001290658 us-gaap:PreferredStockMember 2022-07-01 2022-09-30
0001290658 us-gaap:CommonStockMember 2022-07-01 2022-09-30
0001290658 us-gaap:AdditionalPaidInCapitalMember 2022-07-01
2022-09-30 0001290658 us-gaap:RetainedEarningsMember 2022-07-01
2022-09-30 0001290658 us-gaap:PreferredStockMember 2022-01-01
2022-09-30 0001290658 us-gaap:CommonStockMember 2022-01-01
2022-09-30 0001290658 us-gaap:AdditionalPaidInCapitalMember
2022-01-01 2022-09-30 0001290658 us-gaap:RetainedEarningsMember
2022-01-01 2022-09-30 0001290658 us-gaap:PreferredStockMember
2021-07-01 2021-09-30 0001290658 us-gaap:CommonStockMember
2021-07-01 2021-09-30 0001290658
us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30
0001290658 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30
0001290658 us-gaap:PreferredStockMember 2021-01-01 2021-09-30
0001290658 us-gaap:CommonStockMember 2021-01-01 2021-09-30
0001290658 us-gaap:AdditionalPaidInCapitalMember 2021-01-01
2021-09-30 0001290658 us-gaap:RetainedEarningsMember 2021-01-01
2021-09-30 0001290658 us-gaap:PreferredStockMember 2022-09-30
0001290658 us-gaap:CommonStockMember 2022-09-30 0001290658
us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001290658
us-gaap:RetainedEarningsMember 2022-09-30 0001290658
us-gaap:PreferredStockMember 2021-09-30 0001290658
us-gaap:CommonStockMember 2021-09-30 0001290658
us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001290658
us-gaap:RetainedEarningsMember 2021-09-30 0001290658 2021-09-30
0001290658 ITOX:UnsecuredConvertiblePromissoryNoteMember 2022-04-01
2022-04-04 0001290658 ITOX:UnsecuredConvertiblePromissoryNoteMember
2022-04-04 0001290658 ITOX:UnsecuredConvertiblePromissoryNoteMember
2022-04-21 0001290658 ITOX:UnsecuredConvertiblePromissoryNoteMember
2022-07-01 2022-09-30 0001290658
ITOX:UnsecuredConvertiblePromissoryNoteMember 2022-01-01 2022-09-30
0001290658 ITOX:UnsecuredConvertiblePromissoryNoteMember 2022-09-30
0001290658 srt:ChiefExecutiveOfficerMember 2020-06-01 2020-06-11
0001290658 ITOX:StockIncentivePlan2022Member
srt:ChiefExecutiveOfficerMember 2022-01-01 2022-09-30 0001290658
ITOX:StockIncentivePlan2022Member srt:ChiefExecutiveOfficerMember
2023-04-01 0001290658 ITOX:StockIncentivePlan2022Member
srt:ChiefExecutiveOfficerMember 2024-04-01 0001290658
ITOX:StockIncentivePlan2022Member srt:ChiefExecutiveOfficerMember
2025-04-01 0001290658 srt:ChiefExecutiveOfficerMember 2022-09-30
0001290658 srt:ChiefExecutiveOfficerMember 2021-12-31 0001290658
srt:ChiefOperatingOfficerMember 2020-06-01 2020-06-11 0001290658
ITOX:Plan2019Member srt:ChiefExecutiveOfficerMember 2022-09-30
0001290658 ITOX:Plan2019Member ITOX:April12023Member 2022-06-02
0001290658 ITOX:Plan2019Member ITOX:April12024Member 2022-06-02
0001290658 ITOX:Plan2019Member ITOX:April120241Member 2022-06-02
0001290658 srt:ChiefOperatingOfficerMember 2022-09-30 0001290658
srt:ChiefOperatingOfficerMember 2021-12-31 0001290658
us-gaap:ConvertibleNotesPayableMember 2022-09-30 0001290658
us-gaap:ConvertibleNotesPayableMember 2021-12-31 0001290658
ITOX:ConvertibleNotesPayableOneMember 2022-09-30 0001290658
ITOX:ConvertibleNotesPayableOneMember 2021-12-31 0001290658
ITOX:ConvertibleNotesPayableTwoMember 2022-09-30 0001290658
ITOX:ConvertibleNotesPayableTwoMember 2021-12-31 0001290658
ITOX:ConvertibleNotesPayableThreeMember 2022-09-30 0001290658
ITOX:ConvertibleNotesPayableThreeMember 2021-12-31 0001290658
ITOX:ConvertibleNotesPayableFourMember 2022-09-30 0001290658
ITOX:ConvertibleNotesPayableFourMember 2021-12-31 0001290658
ITOX:ConvertibleNotesPayableFiveMember 2022-09-30 0001290658
ITOX:ConvertibleNotesPayableFiveMember 2021-12-31 0001290658
ITOX:NoteAMember us-gaap:CommonStockMember 2022-05-01 2022-05-23
0001290658 ITOX:NoteAMember us-gaap:CommonStockMember 2022-05-23
0001290658 ITOX:NoteAMember 2022-07-01 2022-09-30 0001290658
ITOX:NoteAMember 2022-01-01 2022-09-30 0001290658 ITOX:NoteAMember
2021-07-01 2021-09-30 0001290658 ITOX:NoteAMember 2021-01-01
2021-09-30 0001290658 ITOX:NoteAMember 2022-09-30 0001290658
ITOX:NoteAMember 2021-12-31 0001290658 ITOX:NoteBMember 2022-07-01
2022-09-30 0001290658 ITOX:NoteBMember 2022-01-01 2022-09-30
0001290658 ITOX:NoteBMember 2021-07-01 2021-09-30 0001290658
ITOX:NoteBMember 2021-01-01 2021-09-30 0001290658 ITOX:NoteBMember
2022-09-30 0001290658 ITOX:NoteBMember 2021-12-31 0001290658
ITOX:NoteDMember 2022-07-01 2022-09-30 0001290658 ITOX:NoteDMember
2022-01-01 2022-09-30 0001290658 ITOX:NoteDMember 2021-07-01
2021-09-30 0001290658 ITOX:NoteDMember 2021-01-01 2021-09-30
0001290658 ITOX:NoteDMember 2022-09-30 0001290658 ITOX:NoteDMember
2021-12-31 0001290658 ITOX:NoteEMember 2021-07-23 2021-08-02
0001290658 ITOX:NoteEMember 2022-07-01 2022-09-30 0001290658
ITOX:NoteEMember 2022-01-01 2022-09-30 0001290658 ITOX:NoteEMember
2021-07-01 2021-09-30 0001290658 ITOX:NoteEMember 2021-01-01
2021-09-30 0001290658 ITOX:NoteEMember 2022-09-30 0001290658
ITOX:NoteEMember 2021-12-31 0001290658 ITOX:NoteFMember 2022-04-02
2022-04-29 0001290658 ITOX:ConvertiblePromissoryNoteholderFMember
ITOX:EquityFinancingAgrMember 2022-04-29 0001290658
ITOX:ConvertiblePromissoryNoteholderFMember
ITOX:EquityFinancingAgrMember 2022-04-02 2022-04-29 0001290658
ITOX:NoteFMember 2022-01-01 2022-09-30 0001290658
ITOX:ConvertiblePromissoryNoteholderGMember 2022-04-02 2022-04-29
0001290658 ITOX:NoteFMember 2022-07-01 2022-09-30 0001290658
ITOX:NoteFMember 2021-07-01 2021-09-30 0001290658 ITOX:NoteFMember
2021-01-01 2021-09-30 0001290658 ITOX:NoteFMember 2022-09-30
0001290658 ITOX:NoteFMember 2021-12-31 0001290658 ITOX:NoteGMember
2022-04-02 2022-04-29 0001290658 ITOX:NoteGMember 2022-01-01
2022-09-30 0001290658 ITOX:NoteGMember 2022-07-01 2022-09-30
0001290658 ITOX:NoteGMember 2021-07-01 2021-09-30 0001290658
ITOX:NoteGMember 2021-01-01 2021-09-30 0001290658 ITOX:NoteGMember
2022-09-30 0001290658 ITOX:NoteGMember 2021-12-31 0001290658
us-gaap:WarrantMember 2022-01-01 2022-09-30 0001290658
us-gaap:WarrantMember 2021-01-01 2021-09-30 0001290658
us-gaap:ConvertibleNotesPayableMember 2022-01-01 2022-09-30
0001290658 us-gaap:ConvertibleNotesPayableMember 2021-01-01
2021-09-30 0001290658
ITOX:UnvestedSharesToDirectorsAndOfficersMember 2022-01-01
2022-09-30 0001290658
ITOX:UnvestedSharesToDirectorsAndOfficersMember 2021-01-01
2021-09-30 0001290658 ITOX:VestedSharesToAConsultantMember
2022-01-01 2022-09-30 0001290658
ITOX:VestedSharesToAConsultantMember 2021-01-01 2021-09-30
0001290658 ITOX:StockholderMember 2022-09-30 0001290658
ITOX:StockholderMember 2021-12-31 0001290658 ITOX:StockholderMember
2022-07-01 2022-09-30 0001290658 ITOX:StockholderMember 2021-07-01
2021-09-30 0001290658 ITOX:StockholderMember 2021-01-01 2021-09-30
0001290658 ITOX:CommonStockPurchaseAgreementMember 2022-01-27
2022-09-30 0001290658 ITOX:ConsultantMember 2022-02-02 2022-02-23
0001290658 ITOX:Plan2017Member 2022-09-30 0001290658
ITOX:Plan2019Member 2022-09-30 0001290658
ITOX:StockIncentivePlan2022Member 2022-09-30 0001290658
ITOX:StockIncentivePlan2022Member srt:OfficerMember 2022-07-01
2022-09-30 0001290658 ITOX:StockIncentivePlan2022Member
srt:DirectorMember 2022-07-01 2022-09-30 0001290658
ITOX:StockIncentivePlan2022Member 2022-07-01 2022-09-30 0001290658
ITOX:StockIncentivePlan2022Member 2022-01-01 2022-09-30 0001290658
ITOX:SeriesASupervotingMember 2020-07-02 0001290658
ITOX:SeriesBConvertiblePreferredStockMember 2020-11-16 0001290658
ITOX:SeriesBConvertiblePreferredStockMember
ITOX:November192020Member 2020-11-18 2020-11-19 0001290658
ITOX:SeriesBConvertiblePreferredStockMember
ITOX:November192020Member 2020-11-19 0001290658
ITOX:SeriesBConvertiblePreferredStockMember
ITOX:November192020Member 2022-07-01 2022-09-30 0001290658
ITOX:SeriesBConvertiblePreferredStockMember
ITOX:November192020Member 2021-07-01 2021-09-30 0001290658
ITOX:SeriesBConvertiblePreferredStockMember
ITOX:November192020Member 2022-01-01 2022-09-30 0001290658
ITOX:SeriesBConvertiblePreferredStockMember
ITOX:November192020Member 2021-01-01 2021-09-30 0001290658
ITOX:SeriesBConvertiblePreferredStockMember
ITOX:November192020Member 2022-09-30 0001290658
ITOX:SeriesBConvertiblePreferredStockMember
ITOX:November192020Member 2021-12-31 0001290658
ITOX:SecuritiesPurchaseAgrMember 2020-12-01 2020-12-16 0001290658
ITOX:SeriesBConvertiblePreferredStockMember
ITOX:December162020Member 2020-12-15 2020-12-16 0001290658
ITOX:SeriesBConvertiblePreferredStockMember
ITOX:December162020Member 2020-12-16 0001290658
us-gaap:ConvertiblePreferredStockMember ITOX:December162020Member
2022-07-01 2022-09-30 0001290658
us-gaap:ConvertiblePreferredStockMember ITOX:December162020Member
2021-07-01 2021-09-30 0001290658
us-gaap:ConvertiblePreferredStockMember ITOX:December162020Member
2022-01-01 2022-09-30 0001290658
us-gaap:ConvertiblePreferredStockMember ITOX:December162020Member
2021-01-01 2021-09-30 0001290658
ITOX:SeriesBConvertiblePreferredStockMember
ITOX:December162020Member 2022-07-01 2022-09-30 0001290658
ITOX:SeriesBConvertiblePreferredStockMember
ITOX:December162020Member 2021-07-01 2021-09-30 0001290658
ITOX:SeriesBConvertiblePreferredStockMember
ITOX:December162020Member 2022-01-01 2022-09-30 0001290658
ITOX:SeriesBConvertiblePreferredStockMember
ITOX:December162020Member 2021-01-01 2021-09-30 0001290658
ITOX:SeriesBConvertiblePreferredStockMember
ITOX:December162020Member 2022-09-30 0001290658
ITOX:SeriesBConvertiblePreferredStockMember
ITOX:December162020Member 2021-12-31 0001290658
ITOX:SeriesBConvertiblePreferredStockMember
ITOX:February72022Member 2022-02-06 2022-02-07 0001290658
ITOX:SeriesBConvertiblePreferredStockMember
ITOX:February72022Member 2022-02-07 0001290658
ITOX:SeriesBConvertiblePreferredStockMember
ITOX:February72022Member 2022-07-01 2022-09-30 0001290658
ITOX:SeriesBConvertiblePreferredStockMember
ITOX:February72022Member 2022-01-01 2022-09-30 0001290658
ITOX:SeriesBConvertiblePreferredStockMember
ITOX:February72022Member 2022-09-30 0001290658
ITOX:SeriesBConvertiblePreferredStockMember ITOX:March242022Member
2022-03-23 2022-03-24 0001290658
ITOX:SeriesBConvertiblePreferredStockMember ITOX:March242022Member
2022-03-24 0001290658 us-gaap:ConvertiblePreferredStockMember
ITOX:March242022Member 2022-07-01 2022-09-30 0001290658
us-gaap:ConvertiblePreferredStockMember ITOX:March242022Member
2022-01-01 2022-09-30 0001290658
ITOX:SeriesBConvertiblePreferredStockMember ITOX:March242022Member
2022-07-01 2022-09-30 0001290658
ITOX:SeriesBConvertiblePreferredStockMember ITOX:March242022Member
2022-01-01 2022-09-30 0001290658
ITOX:SeriesBConvertiblePreferredStockMember ITOX:March242022Member
2022-09-30 0001290658 ITOX:SeriesBConvertiblePreferredStockMember
2022-07-01 2022-09-30 0001290658
ITOX:SeriesBConvertiblePreferredStockMember 2022-01-01 2022-09-30
0001290658 ITOX:SeriesBConvertiblePreferredStockMember 2021-07-01
2021-09-30 0001290658 ITOX:SeriesBConvertiblePreferredStockMember
2021-01-01 2021-09-30 iso4217:USD xbrli:shares iso4217:USD
xbrli:shares xbrli:pure
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
10-Q
(Mark One)
☒ |
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|
|
|
|
|
For
the quarterly period ended
September 30, 2022 |
Or
☐ |
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15
(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|
|
|
|
|
For
the transition period from
_______________________to___________________________ |
Commission File Number:
000-50773
IIOT-OXYS, INC.
(Exact name of registrant as specified in its charter)
Nevada |
56-2415252 |
(State
or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
|
|
705 Cambridge Street,
Cambridge,
MA |
02141 |
(Address of principal executive
offices) |
(Zip
Code) |
(401)
307-3092
(Registrant’s telephone number, including area code)
Securities registered pursuant to section 12(b) of the Act:
Title of Each
Class |
|
Trading Symbol(s) |
|
Name of each exchange on which
registered |
Not
applicable |
|
Not
applicable |
|
Not
applicable |
Indicate by check mark whether the registrant has filed all reports
required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such
reports).
Yes ☒ No ☐
Indicate by check mark whether the registrant has been subject to
such filing requirements for the past 90 days.
Yes ☒ No
☐
Indicate by check mark whether the registrant has submitted
electronically every Interactive Data File required to be submitted
pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter)
during the preceding 12 months (or for such shorter period that the
registrant was required to submit such files).
Yes ☒ No
☐
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, a
smaller reporting company, or an emerging growth company. See the
definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule
12b-2 of the Exchange Act.
|
Large
accelerated filer |
☐ |
Accelerated
filer |
☐ |
|
Non-accelerated
filer |
☒ |
Smaller reporting
company |
☒ |
|
|
|
Emerging growth
company |
☒ |
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act). Yes ☐
No ☒
The
number of shares outstanding of the registrant’s common stock on
November 9, 2022, was
321,578,761.
TABLE OF
CONTENTS
Introductory Comment
Unless otherwise indicated, any reference to “the Company”, “our
company”, “we”, “us”, or “our” refers to IIOT-OXYS, Inc., a Nevada
corporation, and as applicable to its wholly owned subsidiaries,
OXYS Corporation, a Nevada corporation, and HereLab, Inc., a
Delaware corporation.
PART I—FINANCIAL
INFORMATION
Item 1. Financial
Statements
IIOT-OXYS,
Inc. and Subsidiaries
Consolidated
Balance Sheets
|
|
|
|
|
|
|
|
|
|
|
September 30,
2022
|
|
|
December 31,
2021
|
|
|
|
(Unaudited) |
|
|
|
|
|
ASSETS |
|
|
|
|
|
|
|
|
Current Assets |
|
|
|
|
|
|
|
|
Cash
and cash equivalents |
|
$ |
34,284 |
|
|
$ |
46,821 |
|
Accounts
receivable |
|
|
16,380 |
|
|
|
11,280 |
|
Prepaid
expenses |
|
|
7,773 |
|
|
|
7,773 |
|
Total Current
Assets |
|
|
58,437 |
|
|
|
65,874 |
|
|
|
|
|
|
|
|
|
|
Note receivable,
net of discount of $5,661 as of September 30, 2022 and
$0 at December 31, 2021,
respectively |
|
|
194,339 |
|
|
|
– |
|
Intangible
assets, net |
|
|
261,062 |
|
|
|
298,085 |
|
|
|
|
|
|
|
|
|
|
Total
Assets |
|
$ |
513,838 |
|
|
$ |
363,959 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND
STOCKHOLDERS' EQUITY (DEFICIT) |
|
|
|
|
|
|
|
|
Current Liabilities |
|
|
|
|
|
|
|
|
Accounts
payable |
|
$ |
159,583 |
|
|
$ |
161,171 |
|
Accrued
liabilities |
|
|
327,554 |
|
|
|
247,155 |
|
Deferred
revenue |
|
|
46,425 |
|
|
|
46,425 |
|
Notes
payable, net of discounts of $0 and $57,148 at September 30, 2022 and
December 31, 2021, respectively |
|
|
363,167 |
|
|
|
233,167 |
|
Salaries payable
to related parties |
|
|
284,452 |
|
|
|
273,926 |
|
Shares payable to
officers |
|
|
12,221 |
|
|
|
– |
|
Unearned
interest |
|
|
10,192 |
|
|
|
– |
|
Derivative liability |
|
|
328,839 |
|
|
|
212,816 |
|
Total Current
Liabilities |
|
|
1,532,433 |
|
|
|
1,174,660 |
|
|
|
|
|
|
|
|
|
|
Notes payable |
|
|
104,300 |
|
|
|
267,152 |
|
Due to
stockholders |
|
|
1,000 |
|
|
|
1,000 |
|
Total
Liabilities |
|
|
1,637,733 |
|
|
|
1,442,812 |
|
|
|
|
|
|
|
|
|
|
Commitments and Contingencies (Note
4) |
|
|
– |
|
|
|
– |
|
|
|
|
|
|
|
|
|
|
Series B
convertible preferred stock, 600 shares
designated, $0.001 par value, $1,200 stated
value; 342
shares and 155
shares issued and outstanding at September 30, 2022 and December
31, 2021, respectively. Liquidation Preference $410,400
and $186,000
as of September 30, 2022 and December 31, 2021, respectively |
|
|
410,400 |
|
|
|
186,000 |
|
|
|
|
|
|
|
|
|
|
Stockholders' Equity (Deficit) |
|
|
|
|
|
|
|
|
Preferred Stock, $0.001 Par Value,
10,000,000
shares authorized; 25,896
shares and 25,845
shares issued and outstanding at September 30, 2022 and December
31, 2021, respectively |
|
|
26 |
|
|
|
26 |
|
Common
Stock $0.001 par value,
1,000,000,000
shares authorized; 309,083,423
Shares and 220,254,395
Shares Issued and Outstanding at September 30, 2022 and December
31, 2021, respectively |
|
|
309,083 |
|
|
|
220,255 |
|
Additional paid in capital |
|
|
7,162,069 |
|
|
|
7,059,098 |
|
Accumulated deficit |
|
|
(9,005,473 |
) |
|
|
(8,544,232 |
) |
Total
Stockholders' Equity (Deficit) |
|
|
(1,534,295 |
) |
|
|
(1,264,853 |
) |
|
|
|
|
|
|
|
|
|
Total
Liabilities and Stockholders' Equity (Deficit) |
|
$ |
513,838 |
|
|
$ |
363,959 |
|
The accompanying notes are an integral part of these unaudited
condensed consolidated financial statements.
IIOT-OXYS,
Inc. and Subsidiaries
Consolidated
Statements of Operations
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For
the three months ended
September 30, |
|
|
For
the nine months ended
September 30, |
|
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
Revenues |
|
$ |
23,003 |
|
|
$ |
5,280 |
|
|
$ |
39,503 |
|
|
$ |
5,280 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of Sales |
|
|
5,140 |
|
|
|
1,275 |
|
|
|
5,650 |
|
|
|
1,275 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross Profit |
|
|
17,863 |
|
|
|
4,005 |
|
|
|
33,853 |
|
|
|
4,005 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of
intangible assets |
|
|
12,477 |
|
|
|
12,477 |
|
|
|
37,023 |
|
|
|
37,295 |
|
General
and administrative |
|
|
158,818 |
|
|
|
208,531 |
|
|
|
543,449 |
|
|
|
737,746 |
|
Total Operating
Expenses |
|
|
171,295 |
|
|
|
221,008 |
|
|
|
580,472 |
|
|
|
775,041 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Income (Expense) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain
(Loss) on change in fair value of derivative liability |
|
|
125,568 |
|
|
|
(18,103 |
) |
|
|
277,424 |
|
|
|
172,558 |
|
Loss on
derivatives |
|
|
(5,504 |
) |
|
|
– |
|
|
|
(207,447 |
) |
|
|
– |
|
Gain (loss) on
extinguishment of debt |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
120,000 |
|
Interest
income |
|
|
5,986 |
|
|
|
– |
|
|
|
11,647 |
|
|
|
– |
|
Interest
expense |
|
|
(14,913 |
) |
|
|
(100,701 |
) |
|
|
(278,605 |
) |
|
|
(333,039 |
) |
Other
income |
|
|
– |
|
|
|
10,000 |
|
|
|
– |
|
|
|
10,000 |
|
Total Other
Income (Expense) |
|
|
111,137 |
|
|
|
(108,804 |
) |
|
|
(196,981 |
) |
|
|
(30,481 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Provision for
income tax |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income (Loss) |
|
$ |
(42,295 |
) |
|
$ |
(325,807 |
) |
|
$ |
(743,600 |
) |
|
$ |
(801,517 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible
Preferred Stock Dividend |
|
|
(6,909 |
) |
|
|
(5,626 |
) |
|
|
(31,617 |
) |
|
|
(16,694 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income (Loss) Attributable to Common Stockholders |
|
$ |
(49,204 |
) |
|
$ |
(331,433 |
) |
|
$ |
(775,217 |
) |
|
$ |
(818,211 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income (Loss) Per Share Attributable to Common Stockholders -
Basic and Diluted |
|
$ |
(0.00 |
) |
|
$ |
(0.00 |
) |
|
$ |
(0.00 |
) |
|
$ |
(0.00 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average Shares Outstanding Attributable to Common
Stockholders - Basic and Diluted |
|
|
287,269,793 |
|
|
|
209,650,048 |
|
|
|
256,358,480 |
|
|
|
188,036,903 |
|
The accompanying notes are an integral part of these unaudited
condensed consolidated financial statements.
IIOT-OXYS,
Inc. and Subsidiaries
Consolidated
Statements of Stockholders' Equity (Deficit)
(Unaudited)
For the three months ended September 30, 2022
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred Stock |
|
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Additional Paid-In Capital |
|
|
Accumulated Deficit |
|
|
Total Stockholders' Equity
(Deficit) |
|
Balance - June
30, 2022 |
|
|
25,896 |
|
|
$ |
26 |
|
|
|
280,792,951 |
|
|
$ |
280,793 |
|
|
$ |
7,103,833 |
|
|
$ |
(8,956,269 |
) |
|
$ |
(1,571,617 |
) |
Common
Stock Issued for Financing Commitments |
|
|
– |
|
|
|
– |
|
|
|
28,290,472 |
|
|
|
28,290 |
|
|
|
60,002 |
|
|
|
– |
|
|
|
88,292 |
|
Sales
commissions paid on capital raise |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(1,766 |
) |
|
|
– |
|
|
|
(1,766 |
) |
Net loss |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(49,204 |
) |
|
|
(49,204 |
) |
Balance - September 30, 2022 |
|
|
25,896 |
|
|
$ |
26 |
|
|
|
309,083,423 |
|
|
$ |
309,083 |
|
|
$ |
7,162,069 |
|
|
$ |
(9,005,473 |
) |
|
$ |
(1,534,295 |
) |
For the nine months
ended September 30, 2022
|
|
Preferred Stock |
|
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Additional Paid-In Capital |
|
|
Accumulated Deficit |
|
|
Total Stockholders' Equity
(Deficit) |
|
Balance -
December 31, 2021 |
|
|
25,896 |
|
|
$ |
26 |
|
|
|
220,254,396 |
|
|
$ |
220,255 |
|
|
$ |
7,059,098 |
|
|
$ |
(8,544,232 |
) |
|
$ |
(1,264,853 |
) |
Common
Stock Issued for Financing Commitments |
|
|
– |
|
|
|
– |
|
|
|
77,479,027 |
|
|
|
77,478 |
|
|
|
404,179 |
|
|
|
– |
|
|
|
481,657 |
|
Sales
commissions paid on capital raise |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(9,633 |
) |
|
|
– |
|
|
|
(9,633 |
) |
Common
Stock Issued for Services |
|
|
– |
|
|
|
– |
|
|
|
100,000 |
|
|
|
100 |
|
|
|
800 |
|
|
|
– |
|
|
|
900 |
|
Common
stock issued for conversion of convertible note
payables |
|
|
– |
|
|
|
– |
|
|
|
11,250,000 |
|
|
|
11,250 |
|
|
|
78,750 |
|
|
|
– |
|
|
|
90,000 |
|
Beneficial Conversion Feature Associated with
Discounts |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(371,125 |
) |
|
|
313,976 |
|
|
|
(57,149 |
) |
Net Loss |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(775,217 |
) |
|
|
(775,217 |
) |
Balance - September 30, 2022 |
|
|
25,896 |
|
|
$ |
26 |
|
|
|
309,083,423 |
|
|
$ |
309,083 |
|
|
$ |
7,162,069 |
|
|
$ |
(9,005,473 |
) |
|
$ |
(1,534,295 |
) |
For the three months ended September 30, 2021
|
|
Preferred Stock |
|
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Additional Paid-In Capital |
|
|
Accumulated Deficit |
|
|
Total Stockholders' Equity
(Deficit) |
|
Balance - June
30, 2021 |
|
|
25,845 |
|
|
$ |
26 |
|
|
|
197,654,395 |
|
|
$ |
197,655 |
|
|
$ |
6,428,833 |
|
|
$ |
(7,967,456 |
) |
|
$ |
(1,340,942 |
) |
Common
stock issued for conversion of convertible note
payables |
|
|
– |
|
|
|
– |
|
|
|
8,000,000 |
|
|
|
8,000 |
|
|
|
72,000 |
|
|
|
– |
|
|
|
80,000 |
|
Common
stock sold for cash |
|
|
– |
|
|
|
– |
|
|
|
10,200,000 |
|
|
|
10,200 |
|
|
|
142,800 |
|
|
|
– |
|
|
|
153,000 |
|
Commission paid for raising capital |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(3,060 |
) |
|
|
– |
|
|
|
(3,060 |
) |
Net loss |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(331,433 |
) |
|
|
(331,433 |
) |
Balance - September 30, 2021 |
|
|
25,845 |
|
|
$ |
26 |
|
|
|
215,854,395 |
|
|
$ |
215,855 |
|
|
$ |
6,640,573 |
|
|
$ |
(8,298,889 |
) |
|
$ |
(1,442,435 |
) |
For the nine months
ended September 30, 2021
|
|
Preferred Stock |
|
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Additional Paid-In Capital |
|
|
Accumulated Deficit |
|
|
Total Stockholders' Equity
(Deficit) |
|
Balance -
December 31, 2020 |
|
|
25,845 |
|
|
$ |
26 |
|
|
|
145,110,129 |
|
|
$ |
145,111 |
|
|
$ |
4,794,261 |
|
|
$ |
(7,480,678 |
) |
|
$ |
(2,541,280 |
) |
Common
stock issued for conversion of convertible note
payables |
|
|
– |
|
|
|
– |
|
|
|
32,350,978 |
|
|
|
32,351 |
|
|
|
291,169 |
|
|
|
– |
|
|
|
323,520 |
|
Common
stock sold for cash |
|
|
– |
|
|
|
– |
|
|
|
35,500,000 |
|
|
|
35,500 |
|
|
|
497,000 |
|
|
|
– |
|
|
|
532,500 |
|
Beneficial conversion feature discount on notes
payable |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
360,000 |
|
|
|
– |
|
|
|
360,000 |
|
Commission paid for raising capital |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(10,650 |
) |
|
|
– |
|
|
|
(10,650 |
) |
Common
stock issued for accrued compensation |
|
|
– |
|
|
|
– |
|
|
|
2,343,288 |
|
|
|
2,343 |
|
|
|
700,643 |
|
|
|
– |
|
|
|
702,986 |
|
Common
stock issued for services |
|
|
– |
|
|
|
– |
|
|
|
550,000 |
|
|
|
550 |
|
|
|
8,150 |
|
|
|
– |
|
|
|
8,700 |
|
Net loss |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(818,211 |
) |
|
|
(818,211 |
) |
Balance - September 30, 2021 |
|
|
25,845 |
|
|
$ |
26 |
|
|
|
215,854,395 |
|
|
$ |
215,855 |
|
|
$ |
6,640,573 |
|
|
$ |
(8,298,889 |
) |
|
$ |
(1,442,435 |
) |
The accompanying notes are an integral part of these unaudited
condensed consolidated financial statements.
IIOT-OXYS,
Inc. and Subsidiaries
Consolidated Statements of Cash Flows
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
For
the nine months ended September 30, |
|
|
|
2022 |
|
|
2021 |
|
Cash Flows From Operating
Activities |
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(775,217 |
) |
|
$ |
(818,211 |
) |
Adjustments to reconcile net loss to
net cash used by operating activities |
|
|
|
|
|
|
|
|
Gain on
extinguishment of debt |
|
|
– |
|
|
|
(120,000 |
) |
Stock compensation
expense for services |
|
|
900 |
|
|
|
– |
|
Discount on notes
receivable |
|
|
5,661 |
|
|
|
– |
|
Amortization of
debt discount on notes payable and preferred stock |
|
|
37,400 |
|
|
|
269,734 |
|
Amortization of
intangible assets |
|
|
37,023 |
|
|
|
37,295 |
|
Changes in Operating Assets and
Liabilities |
|
|
|
|
|
|
|
|
(Increase) in
prepaid expense |
|
|
– |
|
|
|
(5,346 |
) |
(Increase) in
accounts receivable |
|
|
(5,100 |
) |
|
|
(5,280 |
) |
(Decrease)
increase in accounts payable |
|
|
(1,588 |
) |
|
|
10,167 |
|
Increase in
accrued liabilities |
|
|
80,398 |
|
|
|
84,755 |
|
Increase
(decrease) in derivative liability |
|
|
116,023 |
|
|
|
(172,558 |
) |
Increase in
unearned interest |
|
|
10,192 |
|
|
|
– |
|
Increase in shares
payable to related parties |
|
|
12,221 |
|
|
|
333,950 |
|
Increase (decrease) in salaries payable to related parties |
|
|
10,526 |
|
|
|
(136,417 |
) |
Net Cash Used By
Operating Activities |
|
|
(471,561 |
) |
|
|
(521,911 |
) |
|
|
|
|
|
|
|
|
|
Cash Flows From Investing |
|
|
|
|
|
|
|
|
Cash
paid for note receivable |
|
|
(200,000 |
) |
|
|
– |
|
Cash Used in
Investing Activities |
|
|
(200,000 |
) |
|
|
– |
|
|
|
|
|
|
|
|
|
|
Cash Flows From Financing
Activities |
|
|
|
|
|
|
|
|
Cash received from
sale of common stock |
|
|
481,657 |
|
|
|
521,850 |
|
Cash payments of
offering costs |
|
|
(9,633 |
) |
|
|
– |
|
Cash
received from sale of Series B preferred stock |
|
|
187,000 |
|
|
|
– |
|
Net Cash Provided
By Financing Activities |
|
|
659,024 |
|
|
|
521,850 |
|
|
|
|
|
|
|
|
|
|
Net Decrease in Cash and Cash
Equivalents |
|
|
(12,537 |
) |
|
|
(61 |
) |
|
|
|
|
|
|
|
|
|
Cash and Cash
Equivalents - Beginning of Period |
|
|
46,821 |
|
|
|
103,074 |
|
|
|
|
|
|
|
|
|
|
Cash and Cash
Equivalents - End of Period |
|
$ |
34,284 |
|
|
$ |
103,013 |
|
|
|
|
|
|
|
|
|
|
Supplement Disclosures of Cash Flow
Information |
|
|
|
|
|
|
|
|
Interest paid |
|
$ |
– |
|
|
$ |
– |
|
Income taxes paid |
|
$ |
– |
|
|
$ |
– |
|
|
|
|
|
|
|
|
|
|
Supplemental Disclosures of Non-Cash
Investing and Financing Activities |
|
|
|
|
|
|
|
|
Conversion of convertible notes payable and derivative
liabilities |
|
$ |
– |
|
|
$ |
1,035,206 |
|
Beneficial conversion feature discount on notes payable |
|
$ |
– |
|
|
$ |
360,000 |
|
Effect of
adopting ASU-2020-06 |
|
$ |
57,149 |
|
|
$ |
– |
|
The accompanying notes are an integral part of these unaudited
condensed consolidated financial statements.
IIOT-OXYS, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
September 30, 2022 and 2021
(Unaudited)
NOTE 1 - NATURE OF OPERATIONS,
BASIS OF PRESENTATION AND GOING CONCERN
Unless otherwise indicated, any reference to “the Company”, “our
company”, “we”, “us”, or “its” refers to IIOT-OXYS, Inc., a Nevada
corporation, and as applicable to its wholly-owned subsidiaries,
OXYS Corporation, a Nevada corporation, and HereLab, Inc., a
Delaware corporation.
IIOT-OXYS, Inc., a Nevada corporation (the “Company”) was
established for the purpose of designing, building, testing, and
selling Edge Computing Systems for the Industrial Internet. The
Company is currently devoting substantially all its efforts in
identifying, developing and marketing engineered products, software
and services for applications in the Industrial Internet which
involves collecting and processing data collected from a wide
variety of industrial systems and machines.
The Company was incorporated in the state of New Jersey on October
1, 2003 under the name of Creative Beauty Supply Corporation and
commenced operations as of January 1, 2004. On November 30, 2007,
the Board of Directors approved a plan to dispose of its wholesale
and retail beauty supply business. On May 18, 2015, the Company
changed its name to Gotham Capital Holdings. From January 1, 2009
until July 28, 2017, the Company had no operations. On March 16,
2017, the Board of Directors approved a name change to “IIOT-OXYS,
Inc.” and authorized a change of domicile from New Jersey to
Nevada.
Impact of
COVID-19
During the period ended September 30, 2022, the effects of a new
coronavirus (“COVID-19”) and related actions to attempt to
control its spread began to impact our business. The impact of
COVID-19 on our operating results for the quarter ended September
30, 2022 was limited, in all material respects, due to the
government mandated numerous measures, including closures of
businesses, limitations on movements of individuals and goods, and
the imposition of other restrictive measures, in its efforts to
mitigate the spread of COVID-19 within the country.
On March 11, 2020, the World Health Organization designated
COVID-19 as a global pandemic. Governments around the world have
mandated, and continue to introduce, orders to slow the
transmission of the virus, including but not limited to
shelter-in-place orders, quarantines, significant restrictions on
travel, as well as work restrictions that prohibit many employees
from going to work. Uncertainty with respect to the economic
effects of the pandemic has introduced significant volatility in
the financial markets.
Basis of
Presentation
The accompanying financial statements have been prepared in
accordance with accounting principles generally accepted in the
United States of America (“GAAP”) and include the accounts
of the Company. The financial statements and accompanying notes are
the representations of the Company’s management, who is responsible
for their integrity and objectivity. In the opinion of the
Company’s management, the financial statements reflect all
adjustments, which are normal and recurring in nature, necessary
for fair financial statement presentation.
Going Concern
The accompanying condensed consolidated financial statements have
been prepared assuming that the Company will continue as a going
concern. As shown in the accompanying financial statements, the
Company has suffered continuing operating losses, has a working
capital deficit of $1,473,996, used cash flows in
operating activities of $471,561,
and has an accumulated deficit of $9,005,473 as
of September 30, 2022. These factors, among others, raise a
substantial doubt about the Company’s ability to continue as a
going concern. If the Company is unable to obtain adequate capital,
it could be forced to cease operations. The accompanying financial
statements do not include any adjustments to reflect the
recoverability and classification of recorded asset amounts and
classification of liabilities that might be necessary should the
Company be unable to continue as a going concern.
Management believes that the Company will be able to achieve a
satisfactory level of liquidity to meet the Company’s obligations
for the next twelve months by generating cash through additional
borrowings and/or sale of equity securities, as needed. However,
there can be no assurance that the Company will be able to generate
sufficient liquidity to maintain its operations. The financial
statements do not include any adjustments that might result from
the outcome of these uncertainties.
NOTE 2 - SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES
The following summary of significant accounting policies of the
Company is presented to assist in the understanding of the
Company’s financial statements. These accounting policies conform
to GAAP in all material respects and have been consistently applied
in preparing the accompanying condensed consolidated financial
statements.
Interim Financial
Statements
The accompanying unaudited interim financial statements and related
notes have been prepared in accordance with GAAP for interim
financial information, and in accordance with the rules and
regulations of the United States Securities and Exchange Commission
(“SEC”) with respect to Form 10-Q and Article 8 of Regulation S-X.
Accordingly, they do not include all of the information and
footnotes required by GAAP for complete financial statements. The
unaudited interim financial statements furnished reflect all
adjustments (consisting of normal recurring adjustments) which are,
in the opinion of management, necessary for a fair statement of the
results for the interim periods presented. Interim results are not
necessarily indicative of the results for the full year. These
unaudited interim consolidated financial statements should be read
in conjunction with the audited financial statements of the Company
for the year ended December 31, 2021.
Principles of
Consolidation
The consolidated financial statements for September 30, 2022 and
2021, respectively, include the accounts of Company, and its
wholly-owned subsidiaries OXYS Corporation and HereLab, Inc. All
significant intercompany balances and transactions have been
eliminated.
Reclassifications
Certain amounts in the prior periods presented have been
reclassified to conform to the current period financial statement
presentation. These reclassifications have no effect on previously
reported net income.
Use of
Estimates
The preparation of financial statements in conformity with GAAP
requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during
the reporting period. The Company regularly evaluates estimates and
assumptions related to the valuation of accounts payable, accrued
liabilities and payable to related parties. The Company bases its
estimates and assumptions on current facts, historical experience
and various other factors that it believes to be reasonable under
the circumstances, the results of which form the basis for making
judgments about the carrying values of assets and liabilities and
the accrual of costs and expenses that are not readily apparent
from other sources. The actual results experienced by the Company
may differ materially and adversely from the Company’s estimates.
To the extent there are material differences between the estimates
and the actual results, future results of operations will be
affected.
Cash and Cash
Equivalents
The Company considers all highly liquid instruments with maturity
of three months or less at the time of issuance to be cash
equivalents. The Company did not have any cash equivalents as of
September 30, 2022 and December 31, 2021. The Company reported a
cash balance of $34,284 and $46,821 as of September 30,
2022 and December 31, 2021, respectively.
Accounts Receivable and
Allowance for Doubtful Accounts
Trade accounts receivable are carried at original invoice amount
less an estimate made for doubtful accounts. The Company determines
the allowance for doubtful accounts by identifying potential
troubled accounts and by using historical experience and future
expectations applied to an aging of accounts. Trade accounts
receivable are written off when deemed uncollectible. Recoveries of
trade accounts receivable previously written off are recorded as
income when received. The Company recorded accounts receivable of
$16,380 and $11,280 at September 30,
2022 and December 31, 2021, and no allowance
for doubtful accounts was deemed necessary as of September 30, 2022
and December 31, 2021, respectively.
Long-Lived
Assets
The Company regularly reviews the carrying value and estimated
lives of its long-lived assets to determine whether indicators of
impairment may exist that warrant adjustments to the carrying value
or estimated useful lives. The determinants used for this
evaluation include management’s estimate of the asset’s ability to
generate positive income from operations and positive cash flow in
future periods as well as the strategic significance of the assets
to the Company’s business objectives.
Definite-lived intangible assets are amortized on a straight-line
basis over the estimated periods benefited and are reviewed when
appropriate for possible impairment.
Basic and Diluted
Earnings (Loss) Per Common Share
The Company computes earnings (loss) per share in accordance with
Financial Accounting Standards Board Accounting Standards
Codification (“ASC”), ASC 260, “Earnings per Share”.
ASC 260 requires presentation of both basic and diluted earnings
per share (“EPS”) on the face of the income statement. Basic
EPS is computed by dividing net income (loss) available to common
shareholders (numerator) by the weighted average number of shares
outstanding (denominator) during the period. Diluted EPS gives
effect to all dilutive potential common shares outstanding during
the period using the treasury stock method and convertible note and
preferred stock using the if-converted method. In computing diluted
EPS, the average stock price for the period is used in determining
the number of shares assumed to be purchased from the exercise of
stock options or warrants. Diluted EPS excludes all dilutive
potential shares if their effect is anti-dilutive.
Revenue
Recognition
The Company’s revenue is derived primarily from providing services
under contractual agreements. The Company recognizes revenue in
accordance with ASC Topic No. 606, Revenue from Contracts with
Customers (“ASC 606”) which was adopted on January 1, 2018.
According to ASC 606, the Company recognizes revenue based on the
following criteria:
|
· |
Identification of a contract or contracts, with a
customer. |
|
· |
Identification of the performance obligations in
the contract. |
|
· |
Determination of contract price. |
|
· |
Allocation of transaction price to the
performance obligation. |
|
· |
Recognition of revenue when, or as, performance
obligation is satisfied. |
The Company used a practical expedient available under ASC
606-10-65-1(f)4 that permits it to consider the aggregate effect of
all contract modifications that occurred before the beginning of
the earliest period presented when identifying satisfied and
unsatisfied performance obligations, transaction price, and
allocating the transaction price to the satisfied and unsatisfied
performance obligations.
The Company has elected to treat shipping and handling activities
as cost of sales. Additionally, the Company has elected to record
revenue net of sales and other similar taxes.
Concentration of Credit
Risk
Financial instruments that potentially expose the Company to
concentrations of risk consist primarily of cash and cash
equivalents which are generally not collateralized. The Company’s
policy is to place its cash and cash equivalents with high quality
financial institutions, in order to limit the amount of credit
exposure. Accounts at each institution are insured by the Federal
Deposit Insurance Corporation (“FDIC”), up to $250,000. At September 30, 2022
and December 31, 2021, the Company had no amounts
in excess of the FDIC insurance limit.
Fair Value of Financial
Instruments and Fair Value Measurements
ASC 820, “Fair Value Measurements and Disclosures”, requires
an entity to maximize the use of observable inputs and minimize the
use of unobservable inputs when measuring fair value. ASC 820
establishes a fair value hierarchy based on the level of
independent, objective evidence surrounding the inputs used to
measure fair value. A financial instrument’s categorization within
the fair value hierarchy is based upon the lowest level of input
that is significant to the fair value measurement. ASC 820
prioritizes the inputs into three levels that may be used to
measure fair value:
Level 1 applies to assets or liabilities for which there are quoted
prices in active markets for identical assets or liabilities.
Level 2 applies to assets or liabilities for which there are inputs
other than quoted prices that are observable for the asset or
liability such as quoted prices for similar assets or liabilities
in active markets; quoted prices for identical assets or
liabilities in markets with insufficient volume or infrequent
transactions (less active markets); or model-derived valuations in
which significant inputs are observable or can be derived
principally from, or corroborated by, observable market data. If
the asset or liability has a specified (contractual) term, the
Level 2 input must be observable for substantially the full term of
the asset or liability.
Level 3 applies to assets or liabilities for which there are
unobservable inputs to the valuation methodology that are
significant to the measurement of the fair value of the assets or
liabilities.
The Company’s consolidated financial instruments consist of cash
and cash equivalents, accounts receivable, prepaid expenses,
accounts payable, accrued liabilities, notes payable and related
parties payable. The Company believes that the recorded values of
all the financial instruments approximate their current fair values
because of their nature and respective maturity dates or
durations.
Income
Taxes
The Company accounts for income taxes using the asset and liability
method in accordance with ASC 740, “Income Taxes”. The asset
and liability method provide that deferred tax assets and
liabilities are recognized for the expected future tax consequences
of temporary differences between the financial reporting and tax
basis of assets and liabilities, and for operating loss and tax
credit carry forwards. Deferred tax assets and liabilities are
measured using the currently enacted tax rates and laws. The
Company records a valuation allowance to reduce deferred tax assets
to the amount that is believed more likely than not to be
realized.
The Company follows the provisions of ASC 740-10, “Accounting
for Uncertain Income Tax Positions.” When tax returns are
filed, it is highly certain that some positions taken would be
sustained upon examination by the taxing authorities, while others
are subject to uncertainty about the merits of the position taken
or the amount of the position that would be ultimately sustained.
In accordance with the guidance of ASC 740-10, the benefit of a tax
position is recognized in the financial statements in the period
during which, based on all available evidence, management believes
it is more likely than not that the position will be sustained upon
examination, including the resolution of appeals or litigation
processes, if any. Tax positions taken are not offset or aggregated
with other positions. Tax positions that meet the
more-likely-than-not recognition threshold are measured as the
largest amount of tax benefit that is more than 50 percent likely
of being realized upon settlement with the applicable taxing
authority. The portion of the benefits associated with tax
positions taken that exceeds the amount measured as described above
should be reflected as a liability for unrecognized tax benefits in
the accompanying consolidated balance sheets along with any
associated interest and penalties that would be payable to the
taxing authorities upon examination.
Convertible Debt and
Convertible Preferred Stock
When the Company issues convertible debt or convertible preferred
stock, it first evaluates the balance sheet classification of the
convertible instrument in its entirety to determine whether the
instrument should be classified as a liability under ASC 480,
Distinguishing Liabilities from Equity, and second whether
the conversion feature should be accounted for separately from the
host instrument. A conversion feature of a convertible debt
instrument or certain convertible preferred stock would be
separated from the convertible instrument and classified as a
derivative liability if the conversion feature, were it a
standalone instrument, meets the definition of an “embedded
derivative” in ASC 815, Derivatives and Hedging. Generally,
characteristics that require derivative treatment include, among
others, when the conversion feature is not indexed to the Company’s
equity, as defined in ASC 815-40, or when it must be settled either
in cash or by issuing stock that is readily convertible to cash.
When a conversion feature meets the definition of an embedded
derivative, it would be separated from the host instrument and
classified as a derivative liability carried on the consolidated
balance sheet at fair value, with any changes in its fair value
recognized currently in the consolidated statements of
operations.
Effective January 1, 2022, we early adopted ASU 2020-06,
“Debt—Debt with Conversion and Other Options (Subtopic
470-20) and Derivatives and Hedging—Contracts in Entity’s Own
Equity (Subtopic 815-40): Accounting for Convertible
Instruments and Contracts in an Entity’s Own Equity” using the
modified retrospective method of adoption. ASU 2020-06 simplifies
the accounting for convertible instruments by removing certain
separation models in Subtopic 470- 20, Debt—Debt with Conversion
and Other Options, for convertible instruments. Under ASU
2020-06, the embedded conversion features no longer are separated
from the host contract for convertible instruments with conversion
features that are not required to be accounted for as derivatives
under Topic 815, Derivatives and Hedging, or that do not result in
substantial premiums accounted for as paid-in capital.
Consequently, a convertible debt instrument will be accounted for
as a single liability measured at its amortized cost as long as no
other features require bifurcation and recognition as derivatives.
By removing those separation models, the interest rate of
convertible debt instruments typically will be closer to the coupon
interest rate when applying the guidance in Topic 835, Interest. We
now account for our Convertible Notes as single liabilities
measured at amortized cost. As a result, the adoption of the
guidance had a material impact on the consolidated financial
statements and accompanying notes, resulting in adjustments of
$371,125, $313,976 and $57,149 to the opening balance of additional
paid-in capital, retained earnings, and long-term debt,
respectively, as of January 1, 2022. We have updated our debt note
(Note 5) with additional and modified disclosures as required
by the standard upon adoption.
Recent Accounting
Pronouncements
In December 2019, the Financial Accounting Standards Board issued
Accounting Standards Update (“ASU”) ASU No. 2019-12,
Income Taxes (Topic 740), Simplifying the Accounting for
Income Taxes, which is intended to simplify various aspects related
to accounting for income taxes. ASU 2019-12 removes certain
exceptions to the general principles in Topic 740 and also
clarifies and amends existing guidance to improve consistent
application. This guidance is effective for fiscal years, and
interim periods within those fiscal years, beginning after December
15, 2021, and interim periods within fiscal years beginning after
December 15, 2022, with early adoption permitted. The Company is
currently evaluating the impact of this guidance on its
consolidated financial statements.
Other accounting standards that have been issued or proposed by
FASB and do not require adoption until a future date are not
expected to have a material impact on the consolidated financial
statements upon adoption. The Company does not discuss recent
pronouncements that are not anticipated to have an impact on or are
unrelated to its financial condition, results of operations, cash
flows or disclosures.
NOTE
3 - NOTE
RECEIVABLE
On April 4, 2022, the Company executed an unsecured convertible
promissory note with the principal sum of $200,000 (“Note”) with a
company incorporated under the laws of the Province of British
Columbia. The Note bears an original issuance discount of $7,500
and matures on April 4, 2024. The interest on the Note will begin
to accrue at the rate of 10% per annum from the date of the Note,
and will continue to accrue on the outstanding principal until the
entire balance is paid or converted into shares of common stock
equal to 3.23% of the fully diluted share capital of the borrower
on the conversion date. The terms of the Note require the borrower
to prepay (i) within 30 days of April 4, 2022, the first twelve
months of interest totaling $20,000, and (ii) within six months of
April 4, 2022, the interest for the second twelve months under the
Note totaling $20,000. The Company will have the right, at its
option on the maturity date, to convert all the principal sum into
the common stock equal to 3.23% of the fully diluted share capital
of the borrower as of the conversion date. On April 4, 2022, the
Company paid to the borrower $192,500 and
recorded an original issuance discount on note receivable of
$7,500. On
April 21, 2022, the Company received $20,000 as prepaid interest
from the borrower. The Company recorded interest income earned on
the Note of $5,041 and $9,808 for the three months
and nine months ended September 30, 2022, and interest income of
$945 and
$1,839
for the three months and nine months ended September 30, 2022. The
Company recorded unearned interest of $10,192 and unamortized
original debt discount of $5,661
at September 30, 2022.
NOTE
4 - INTANGIBLE
ASSETS
The Company’s intangible assets comprise of intellectual property
revolving around their field tests, sensor integrations, and board
designs. Intangible assets, net of amortization at September 30,
2022 and December 31, 2021 amounted to $261,062 and
$298,085,
respectively.
Intangible Assets Net of
Amortization |
|
|
|
|
|
|
|
|
September 30,
2022
|
|
|
December 31,
2021
|
|
Intangible Assets |
|
$ |
495,000 |
|
|
$ |
495,000 |
|
Accumulated
amortization |
|
|
(233,938 |
) |
|
|
(196,915 |
) |
Intangible
Assets, net |
|
$ |
261,062 |
|
|
$ |
298,085 |
|
The Company determined that none of its intangible assets were
impaired as of September 30, 2022 and December 31, 2021,
respectively, Amortizable intangible assets are amortized using the
straight-line method over their estimated useful lives of ten
years. Amortization expense of finite-lived intangibles was
$12,477 and $12,477 for the three months
ended September 30, 2022 and 2021, and $37,023 and $37,295 for the nine months
ended September 30, 2022 and 2021, respectively.
The following table summarizes the Company’s estimated future
amortization expense of intangible assets with finite lives as of
September 30:
Schedule of future amortization |
|
|
|
|
|
|
|
Amortization Expense |
|
2022 (Remainder of the
year) |
|
$ |
12,477 |
|
2023 |
|
|
49,500 |
|
2024 |
|
|
49,500 |
|
2025 |
|
|
49,500 |
|
2026 |
|
|
49,500 |
|
Thereafter |
|
|
50,585 |
|
Total |
|
$ |
261,062 |
|
NOTE 5 - COMMITMENTS AND
CONTINGENCIES
On June 11, 2020, the Company entered into a Debt Forgiveness
Agreement with the CEO, pursuant to which the CEO forgave
$185,000 of accrued and unpaid
consulting fees owed to him pursuant to his consulting agreement
with the Company. On June 12, 2020, the Company entered into an
amendment effective January 1, 2020 to the Consulting Agreement
with the CEO. The amendment stated that from January 1, 2020 until
April 23, 2020, the Consultant shall be paid an hourly wage of
$12.75 per hour for services performed. From April 24, 2020 onward,
the Consultant shall be paid an hourly wage of $48.08 an hour for
services performed. Fees may accrue at the discretion of
management. At any time, the Consultant shall have the right to
convert any accrued and unpaid fees into shares of Common Stock of
the Company. The conversion price shall equal 90% multiplied by the
market price (representing a discount rate of 10%). On June 4,
2021, the Consulting Agreement of the CEO terminated pursuant to
its terms. On June 2, 2022, the Board approved an Employment
Agreement with the CEO dated effective April 1, 2022 whereby, the
CEO will receive an annual salary of $100,000 which accrues unless
converted into shares of common stock of the Company at a
stipulated conversion rate. If the Company reaches $1,000,000 in
cumulative sales over a 12-month period, the annual salary will
increase to $150,000 commencing the following month. If the Company
reaches $5,000,000 in cumulative sales over a 12-month period, the
annual salary will increase to $200,000 commencing the following
month. The Company awarded the CEO an aggregate of
7,000,000 shares of the Company common stock under the 2022
Stock Incentive Plan, which will vest (i)
1,500,000 shares on April 1, 2023, (ii)
2,500,000 shares on April 1, 2024, and (iii)
3,000,000 shares on April 1, 2025. The Company recorded
$151,204 and $145,844 in salaries payable to the
CEO as of September 30, 2022 and December 31, 2021,
respectively.
On June 11, 2020, the Company entered into a Debt Forgiveness
Agreement with the COO, pursuant to which the COO forgave
$103,250 of accrued and unpaid
consulting fees owed to her pursuant to her consulting agreement
with the Company. On June 12, 2020, the Company entered into
an amendment effective January 1, 2020 to the Consulting Agreement
with the COO. The amendment stated that from January 1, 2020 until
April 23, 2020, the Consultant shall be paid an hourly wage of
$12.75 per hour for services performed. From April 24, 2020 onward,
the Consultant shall be paid an hourly wage of $48.08 an hour for
services performed. Fees may accrue at the discretion of
management. At any time, the Consultant shall have the right to
convert any accrued and unpaid fees into shares of Common Stock of
the Company. The conversion price shall equal 90% multiplied by the
market price (representing a discount rate of 10%).
On June 2, 2022, the Board approved an Employment Agreement with
the COO/Interim CFO dated effective April 1, 2022 whereby, the
officer will receive an annual salary of $100,000 which accrues
unless converted into shares of common stock of the Company at a
stipulated conversion rate. If the Company reaches $1,000,000 in
cumulative sales over a 12-month period, the annual salary will
increase to $150,000 commencing the following month. If the Company
reaches $5,000,000 in cumulative sales over a 12-month period, the
annual salary will increase to $200,000 commencing the following
month. The Company awarded the COO/Interim CFO an aggregate of
7,000,000 shares of
the Company common stock under the 2022 Stock Incentive Plan, which
will vest (i) 1,500,000 shares on
April 1, 2023, (ii) 2,500,000 shares on
April 1, 2024, and (iii) 3,000,000 shares on
April 1, 2024. The Company recorded $133,248 and $145,844 in salaries payable to the
COO as of September 30, 2022 and December 31, 2021,
respectively.
NOTE 6 - CONVERTIBLE NOTES
PAYABLE
The following table summarizes the outstanding balance of
convertible notes payable, interest and conversion rates as of
September 30, 2022 and December 31, 2021, respectively.
|
|
Schedule of convertible notes payable |
|
|
|
|
|
|
|
|
|
|
September 30,
2022
|
|
|
December 31,
2021
|
|
|
|
|
|
|
|
|
|
|
A. |
|
Convertible note payable to an investor with
interest at 12% per annum, convertible at any time into shares of
common stock at $0.008 per share. The balance of principal and
accrued and unpaid interest is payable on maturity on March 1,
2023, unless automatically extended for one-year periods if no
Event of Default is existing. The note is secured by substantially
all the assets of the Company. |
|
$ |
205,000 |
|
|
$ |
295,000 |
|
|
|
|
|
|
|
|
|
|
|
|
B. |
|
Convertible note payable to an investor with
interest at 5% per annum, convertible at any time into shares of
common stock at $0.00084 per share. Interest is payable annually
with the balance of principal and interest due on maturity on March
1, 2024. The note is secured by substantially all the assets of the
Company. |
|
|
55,000 |
|
|
|
55,000 |
|
|
|
|
|
|
|
|
|
|
|
|
D. |
|
Convertible note payable to an investor with
interest at 12% per annum, convertible at any time into shares of
common stock at $0.008 per share. The balance of principal and
accrued and unpaid interest is payable on March 1, 2023, unless
automatically extended for one-year periods if no Event of Default
is existing. The note is secured by substantially all the assets of
the Company. |
|
|
50,000 |
|
|
|
50,000 |
|
|
|
|
|
|
|
|
|
|
|
|
E. |
|
Convertible notes payable to a related party with
interest at 12% per annum, convertible at any time into shares of
common stock at $0.00084 per share. Interest is payable quarterly
with the balance of principal and interest due on maturity on
August 2, 2024. The notes are secured by substantially all the
assets of the Company. |
|
|
125,000 |
|
|
|
125,000 |
|
|
|
|
|
|
|
|
|
|
|
|
F. |
|
Convertible note payable to an investor with
interest at 10% per annum, convertible at any time into shares of
common stock at $0.01 per share. Principal and interest due on
maturity on April 29, 2023. |
|
|
33,167 |
|
|
|
33,167 |
|
|
|
|
|
|
|
|
|
|
|
|
G. |
|
Convertible note payable to an investor with
interest at 10% per annum, convertible at any time into shares of
common stock at $0.0099 per share. Note was issued as payment for
future fees to be incurred under the related Equity Financing
Agreement. Principal and interest due on maturity on April 29,
2023. |
|
|
75,000 |
|
|
|
75,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
543,167 |
|
|
|
633,167 |
|
|
|
Less: deferred financing costs |
|
|
(75,700 |
) |
|
|
(75,700 |
) |
|
|
Less unamortized discount |
|
|
– |
|
|
|
(57,148 |
) |
|
|
Net balance |
|
|
467,467 |
|
|
|
500,319 |
|
|
|
Less current portion |
|
|
(363,167 |
) |
|
|
(233,167 |
) |
|
|
Long term portion |
|
$ |
104,300 |
|
|
$ |
267,152 |
|
A. January 18,
2018 Convertible Note and Warrants (“Note
A”)
On March 14, 2022, the noteholder of Note A agreed to extend the
maturity date of March 1, 2022 of the Senior Secured Convertible
Promissory Note to March 1, 2023, in exchange for the reduction of
the conversion price to $0.008 per share, and all prior Events of
Default (as defined in the Note A) including penalties were waived,
and all future Events of Default (as defined in the Note A)
pertaining to the future payment of interest were waived through
maturity. On May 23, 2022, the noteholder of Note A converted
$90,000 of the
principal note balance into 11,250,000
shares of the Company’s common stock at the conversion price of
$0.008 per share (Note 9).
On January 28, 2021, the
noteholder of Note A agreed to extend the maturity date of the
Senior Secured Convertible Promissory Note to March 1, 2022, in
exchange for the reduction of the conversion price to $0.01 per
share, and all prior Events of Default (as defined in the Note A)
including penalties of $100,000 were waived, and all future Events
of Default (as defined in the Note A) pertaining to the future
payment of interest were waived through maturity. On December 14,
2021, the Company entered into amendment to the Note A which limits
the respective holder to conversions resulting in beneficial
ownership by the holder and its affiliates of no more than 4.99% of
the outstanding shares of common stock of the Company. The Company
recorded $100,000 as extinguishment of debt in its statements of
operations for the year ended December 31, 2021.
The Company recorded interest expense of $6,201 and $22,631 for the three months
and nine months ended September 30, 2022 compared to interest
expense of $9,659 and $36,289 for the same
comparable periods of 2021. Accrued interest payable on Note A was
$153,667 and $131,036 as of September 30, 2022
and December 31, 2021, respectively.
The principal balance payable on Note A amounted to $205,000 and $295,000 on September 30,
2022 and December 31, 2021, respectively.
B. January 2019
Convertible Note and Warrants (“Note B”)
Effective March 1, 2021, the noteholder of Note B agreed to extend
the maturity date of March 1, 2022 of the Senior Secured
Convertible Promissory Note to March 1, 2024, and all prior Events
of Default (as defined in the Note B) including penalties were
waived, and all other terms of the Note B remain the same (Note
9).
The Company recorded interest expense of $693 and $2,057 on Note B for the three
months and nine months ended September 30, 2022 compared to
interest expense of $693 and $2,057 for the same comparable
periods of 2021. Accrued interest payable on Note B was $10,148 and $8,092 as of September 30, 2022 and
December 31, 2021, respectively. The principal balance payable on
Note B amounted to $55,000 and $55,000 on September 30,
2022 and December 31, 2021, respectively.
D. March 2019
Convertible Note and Warrants (“Note D”)
On March 14, 2022, the noteholder of Note D agreed to extend the
maturity date of March 1, 2022 of the Senior Secured Convertible
Promissory Note to March 1, 2023, in exchange for the reduction of
the conversion price to $0.008 per share, and all prior Events of
Default (as defined in the Note D) including penalties were waived,
and all future Events of Default (as defined in the Note D)
pertaining to the future payment of interest were waived through
maturity.
On January 28, 2021, the noteholder of Note D agreed to extend the
maturity date of the Senior Secured Convertible Promissory Note to
March 1, 2022 in exchange for the reduction of the conversion price
to $0.01 per share, and all prior Events of Default (as defined in
the Note D) including penalties of $10,000 were waived, and all
future Events of Default (as defined in the Note D) pertaining to
the future payment of interest were waived through maturity. The
Company recorded $10,000 as extinguishment of debt in its
statements of operations for the nine months ended September 30,
2021.
The Company recorded interest expense of $1,512 and $4,487 on Note D for the three
months and nine months ended September 30, 2022 compared to
interest expense of $1,512 and $4,603 for the same comparable
periods of 2021. Accrued interest payable on Note D was $19,185 and $14,698 as of September 30, 2022 and
December 31, 2021, respectively. The principal balance payable on
Note D amounted to $50,000 on September
30, 2022 and December 31, 2021, respectively.
E. August 2019
Convertible Note and Warrants (“Note E”)
On August 2, 2021, the noteholder of Note E agreed to extend the
maturity date of the Senior Secured Convertible Promissory Note to
August 2, 2024. All
other terms and conditions of the Note E remain the same.
The Company recorded interest expense of $3,781 and $11,219 on Note E for the
three months and nine months ended September 30, 2022 compared to
interest expense of $3,781 and $11,219 for the same
comparable periods of 2021. Accrued interest payable on Note E was
$44,909 and $14,698 as of September 30, 2022 and
December 31, 2021, respectively. The principal balance payable on
Note E amounted to $125,000 and $125,000 on September 30,
2022 and December 31, 2021, respectively.
F. July 2020 Equity
Financing Arrangement (“Note F”)
On April 29, 2022, the noteholder of Note F agreed to extend the
maturity date of the Senior Secured Convertible Promissory Note to
April 29, 2023. All
other terms and conditions of the Note F remain the same. On
February 1, 2021, the noteholder of Note F converted the principal
balance of $66,833 of its
convertible promissory note and $5,177 of accrued interest into
7,200,000
shares of common stock of the Company. On November 4, 2021, the
noteholder of Note F agreed to extend the maturity date of the Note
F from October 29, 2021 to April 29, 2022 in exchange of receiving
625,000 shares
of common stock valued at $5,563
as commitment fee for extending the maturity date of Note F.
The Company recorded interest expense of $836 and $2,481 on Note F for the three
months and nine months ended September 30, 2022 compared to
interest expense of $836 and $3,067 for the same comparable
periods of 2021. Accrued interest payable on Note F was $4,193 and $1,712 as of September 30, 2022 and
December 31, 2021, respectively. The principal balance payable on
Note F amounted to $33,167 on September
30, 2022 and December 31, 2021, respectively.
G . July 2020 Equity
Financing Arrangement (“Note G”)
On April 29, 2022, the noteholder of Note G agreed to extend the
maturity date of the Senior Secured Convertible Promissory Note to
April 29, 2023. All
other terms and conditions of the Note G remain the same. On
November 4, 2021, the noteholder of Note G agreed to extend the
maturity date of the Note G from October 29, 2021 to April 29, 2022
in exchange of receiving 625,000 shares
of common stock valued at $5,563
as commitment fee for extending the maturity date of Note G.
The Company recorded interest expense of $1,890 and $5,610 on Note G for the three
months and nine months ended September 30, 2022 compared to
interest expense of $1,890 and $5,610 for the same comparable
periods of 2021. Accrued interest payable on Note G was $15,349 and $9,740 as of September 30, 2022 and
December 31, 2021, respectively. The principal balance payable of
Note G amounted to $75,000 at September
30, 2022 and December 31, 2021, respectively.
NOTE 7 - EARNINGS (LOSS) PER
SHARE
The following table sets forth the computation of basic and diluted
net loss per share of common stock for the three months and nine
months ended September 30, 2022 and 2021:
Schedule of earnings per share |
|
|
|
|
|
|
|
|
Three Months Ended
September 30, |
|
|
|
2022 |
|
|
2021 |
|
Net loss attributable to
common stockholders (basic) |
|
$ |
(49,204 |
) |
|
$ |
(331,433 |
) |
|
|
|
|
|
|
|
|
|
Shares used to
compute net loss per common share, basic and diluted |
|
|
287,269,793 |
|
|
|
209,650,048 |
|
|
|
|
|
|
|
|
|
|
Net loss per
share attributable to common stockholders, basic and diluted |
|
$ |
(0.00 |
) |
|
$ |
(0.00 |
) |
|
|
|
|
|
|
|
|
|
Nine Months Ended
September 30, |
|
|
|
2022 |
|
|
2021 |
|
Net loss attributable to
common stockholders (basic) |
|
$ |
(775,217 |
) |
|
$ |
(818,211 |
) |
|
|
|
|
|
|
|
|
|
Shares used to
compute net loss per common share, basic and diluted |
|
|
256,358,480 |
|
|
|
188,036,903 |
|
|
|
|
|
|
|
|
|
|
Net loss per
share attributable to common stockholders, basic and diluted |
|
$ |
(0.00 |
) |
|
$ |
(0.00 |
) |
Basic net loss per share is calculated by dividing net loss by the
weighted-average number of common shares outstanding during the
period. Diluted net loss per share is computed by dividing net loss
by the weighted-average number of common shares and common share
equivalents outstanding for the period. Common stock equivalents
are only included when their effect is dilutive. The Company’s
potentially dilutive securities which include stock options,
convertible debt, convertible preferred stock and common stock
warrants have been excluded from the computation of diluted net
loss per share as they would be anti-dilutive. For all periods
presented, there is no difference in the number of shares used to
compute basic and diluted shares outstanding due to the Company’s
net loss position.
The following outstanding common stock equivalents have been
excluded from diluted net loss per common share for the nine months
ended September 30, 2022 and 2021, respectively, because their
inclusion would be anti-dilutive:
Schedule of anti-dilutive shares |
|
|
|
|
|
|
|
|
As of
September 30, |
|
|
|
2022 |
|
|
2021 |
|
Warrants to purchase
common stock |
|
|
2,868,397 |
|
|
|
2,868,397 |
|
Potentially issuable shares related to convertible notes payable
and convertible preferred stock |
|
|
351,967,716 |
|
|
|
322,132,917 |
|
Potentially issuable unvested shares
to directors and officers |
|
|
14,000,000 |
|
|
|
1,200,000 |
|
Potentially
issuable vested shares to a consultant |
|
|
– |
|
|
|
150,000 |
|
Total
anti-dilutive common stock equivalents |
|
|
368,836,113 |
|
|
|
326,351,314 |
|
NOTE 8 - RELATED
PARTIES
At September 30, 2022 and December 31, 2021, respectively, the
amount due to two stockholders was $1,000 relating to
depositing funds for opening bank accounts for the Company.
The Company executed an operating lease to rent its current office
facility from a stockholder on a month-to-month basis at a monthly
rent of $250 starting January 1, 2020. The Company recorded rent
expense of $750 and
$2,250 for
the three months and nine months ended September 30, 2022 and 2021,
respectively. The Company has recorded $1,000 and
$750 of rent
payable to the stockholder in accounts payable as of September 30,
2022 and December 31, 2021, respectively.
NOTE 9 - STOCKHOLDERS'
EQUITY
The Company has an authorized
capital of 1,000,000,000 shares, $0.001 par value
common stock, and 10,000,000
shares of $0.001 par value
preferred stock at September 30, 2022. The Company has 309,083,423
shares and 220,254,396 shares of common stock, and 25,896
shares and 25,845 shares of preferred stock, issued and outstanding
as of September 30, 2022 and December 31, 2021,
respectively.
Common
Stock
Holders of shares of common stock are entitled to one vote for each
share on all matters to be voted on by the stockholders. Holders of
common stock do not have cumulative voting rights. Holders of
common stock are entitled to share ratably in dividends, if any, as
may be declared from time to time by the Board of Directors in its
discretion from funds legally available, therefore. In the event of
liquidation, dissolution, or winding up of the Company, the holders
of common stock are entitled to share pro rata in all assets
remaining after payment in full of all liabilities. All of the
outstanding shares of common stock are fully paid and
non-assessable. Holders of common stock have no preemptive rights
to purchase the Company’s common stock. There are no conversion or
redemption rights or sinking fund provisions with respect to the
common stock.
On February 24, 2021, the Company entered into a Common Stock
Purchase Agreement with an investor pursuant to which the investor
agreed to purchase up to $5,000,000 of the Company’s registered
common stock at $0.015 per share. Pursuant to the Agreement,
purchases may be made by the Company during the Commitment Period
(as defined in the Agreement) through the submission of a purchase
notice to the investor no sooner than ten business days after the
preceding closing. No purchase notice can be made in an amount less
than $10,000 or greater than $500,000 or greater than two times the
average of the daily trading dollar volume for the Company’s common
stock during the ten business days preceding the purchase date.
Each purchase notice is limited to the investor beneficially owning
no more than 4.99% of the total outstanding common stock of the
Company at any given time. There are certain conditions precedent
to each purchase including, among others, an effective registration
statement in place and the VWAP of the closing price of the
Company’s common stock greater than $0.0175 for the Company's
common stock during the five business days prior to the closing.
From January 27, 2022 to September 30, 2022, the investor purchased
77,479,027
shares of common stock for a cash consideration of $481,657. The
shares sold to the investor were valued at 80% of the lowest traded
price of common stock during the ten consecutive days preceding the
relevant purchase date.
On February 23, 2022, the Company issued to a consultant for
services rendered, pursuant to a consulting agreement, 100,000
shares of common stock valued at the fair market price on the date
of issuance of $900.
On May 23, 2022, the noteholder of Note A converted $90,000 of the
principal note balance into 11,250,000 shares of the
Company’s common stock at the agreed conversion price of $0.008 per share (Note 6).
Stock Incentive
Plans
On December 14, 2017, the Board of Directors of the Company
approved the 2017 Stock Incentive Plan (the “2017 Plan”).
Awards may be made under the 2017 Plan for up to 4,500,000 shares of
common stock of the Company. All of the Company’s employees,
officers and directors, as well as consultants and advisors to the
Company are eligible to be granted awards under the 2017 Plan. No
awards can be granted under the 2017 Plan after the expiration of
10 years from the plan approval but awards previously granted may
extend beyond that date. Awards may consist of both incentive and
non-statutory options, restricted stock units, stock appreciation
rights, and restricted stock awards.
On March 11, 2019, the Board of Directors of the Company approved
the 2019 Stock Incentive Plan (the “2019 Plan”). Awards may
be made under the 2019 Plan for up to 5,000,000 shares of
common stock of the Company. All of the Company’s employees,
officers and directors, as well as consultants and advisors to the
Company are eligible to be granted awards under the 2019 Plan. No
awards can be granted under the 2019 Plan after the expiration of
10 years from the plan approval but awards previously granted may
extend beyond that date. Awards may consist of both incentive and
non-statutory options, restricted stock units, stock appreciation
rights, and restricted stock awards.
On March 18, 2022, the Board of Directors approved and adopted the
2022 Stock Incentive Plan (the “2022 Plan”). Awards may be
made under the 2022 Plan for up to 20,000,000 shares
of common stock of the Company, subject to adjustment as to the
number and kind of shares awarded. Only employees and directors of
the Company or an Affiliated company are eligible to receive
Incentive Options under the 2022 Plan. The Company awarded
7,000,000 shares of the Company’s common stock to an officer
and
7,000,000 shares of common stock to a director of the
Company (see Note 4) vesting 1,500,000 shares vesting on the first
anniversary on the date of issuance, 2,500,000 shares vesting on
the second anniversary of the date of issuance, and 3,000,000
shares on the third anniversary of the date of issuance. The common
shares vested pursuant to the 2022 Plan amounted to
0 shares at September 30, 2022 and the
14,000,000 remain unvested as of that date. For the three
months and nine months ended September 30, 2022, the Company
recorded $3,617 and
$12,221 as
stock compensation expense for the 764,384 shares and 1,512,329
shares payable to an officer and a director that remain unvested as
of September 30, 2022.
Shares earned and issued related to the consulting agreements are
issued under the 2017 Stock Incentive Plan and the 2019 Stock
Incentive Plan (Note 4). Vesting of the shares is subject to
acceleration of vesting upon the occurrence of certain events such
as a Change of Control (as defined in the agreement) or the listing
of the Company’s common stock on a senior exchange.
A summary of the status of the Company’s non-vested shares as of
September 30, 2022 and 2021, and changes during the six months
period then ended, is presented below:
Summary of non-vested shares |
|
|
|
|
|
|
2022 Plan |
|
Non-vested Shares of Common Stock |
|
|
Weighted Average Fair Value |
|
Balance at December 31, 2021 |
|
|
– |
|
|
$ |
– |
|
Awarded |
|
|
14,000,000 |
|
|
|
– |
|
Vested |
|
|
– |
|
|
|
0.008081 |
|
Forfeited |
|
|
– |
|
|
|
– |
|
Balance at September 30,
2022 |
|
|
14,000,000 |
|
|
$ |
– |
|
|
|
|
|
|
|
|
|
|
2017 Plan and 2019 Plan |
|
|
|
|
|
|
|
|
Balance at December 31, 2020 |
|
|
3,600,000 |
|
|
$ |
0.30 |
|
Awarded |
|
|
– |
|
|
|
– |
|
Vested |
|
|
(3,600,000 |
) |
|
|
0.30 |
|
Forfeited |
|
|
– |
|
|
|
– |
|
Balance at September 30,
2021 |
|
|
– |
|
|
$ |
0.30 |
|
Preferred
Stock
Series A Supervoting
Convertible Preferred Stock
On July 2, 2020, the Board of Directors of the Company authorized
the issuance of 15,600 shares of
preferred stock, $0.001 par value per
share, designated as Series A Supervoting Convertible Preferred
Stock.
Dividends: Initially,
there will be no dividends due or payable on the Series A
Supervoting Preferred Stock. Any future terms with respect to
dividends shall be determined by the Board consistent with the
Corporation’s Articles of Incorporation.
Liquidation and Redemption
Rights: Upon the occurrence of a Liquidation Event (as
defined below), the holders of Series A Supervoting Preferred Stock
are entitled to receive net assets on a pro-rata basis. Each holder
of Series A Supervoting Preferred Stock is entitled to receive
ratably any dividends declared by the Board, if any, out of funds
legally available for the payment of dividends. Liquidation Event
means (i) the liquidation, dissolution or winding-up, whether
voluntary or involuntary, of the corporation, (ii) the purchase or
redemption by the corporation of the shares of any class of stock
or the merger or consolidation of the corporation with or into any
other corporation or corporations, or (iii) the sale, license or
lease of all or substantially all, or any material part of, the
Corporation’s assets.
Conversion: Each holder of
Series A Supervoting Preferred Stock may voluntarily convert its
shares into shares of common stock of the Corporation at a rate of
1:100 (as may be adjusted for any combinations or splits with
respect to such shares).
Rank: All
shares of the Series A Supervoting Preferred Stock shall rank
senior to the Corporation’s (A) common stock, par value $0.001 per
share, and any other class or series of capital stock of the
Corporation hereafter created.
Voting Rights:
|
A. |
If at
least one share of Series A Super Voting Preferred Stock is issued
and outstanding, then the total aggregate issued shares of Series A
Super Voting Preferred Stock at any given time, regardless of their
number, shall have voting rights equal to 20 times the sum of: i)
the total number of shares of Common stock which are issued and
outstanding at the time of voting, plus ii) the total number of
shares of all Series of Preferred stocks which are issued and
outstanding at the time of voting. |
|
B. |
Each
individual share of Series A Super Voting Preferred Stock shall
have the voting rights equal to: |
[twenty times the sum of: {all shares of Common stock issued and
outstanding at the time of voting + all shares of Series A and any
newly designated Preferred stock issued and outstanding at the time
of voting}]
Divided by:
[the number of shares of Series A Super Voting Preferred Stock
issued and outstanding at the time of voting]
With respect to all matters upon which stockholders are entitled to
vote or to which stockholders are entitled to give
consent, the holders of the outstanding shares of Series A
Super Voting Preferred Stock shall vote together with the holders
of Common Stock without regard to class, except as to those matters
on which separate class voting is required by applicable law or the
Articles of Incorporation or Bylaws.
The Company had 25,896 shares of preferred stock issued and
outstanding at September 30, 2022 and December 31, 2021,
respectively.
Series B Convertible
Preferred Stock Equity Financing
On November 16, 2020, the Board of Directors of the Company
authorized the issuance of up to 600 shares of
preferred stock, $0.001 par value per
share, designated as Series B Convertible Preferred Stock. Each
share of Preferred Stock has a par value of $0.001 per share and a
stated value of $1,200, subject to
increase set forth in the Certificate of Designation.
Dividends: Each share of
Series B Convertible Preferred Stock shall be entitled to receive,
and the Corporation shall pay, cumulative dividends of 12% per
annum, payable quarterly, beginning on the Original Issuance Date
and ending on the date that such share of Series B Convertible
Preferred Share has been converted or redeemed (the “Dividend End
Date”). Dividends may be paid in cash or in shares of Series B
Convertible Preferred Stock. From and after the initial Closing
Date, in addition to the payment of dividends pursuant to Section
2(a), each Holder shall be entitled to receive, and the Corporation
shall pay, dividends on shares of Series B Convertible Preferred
Stock equal to (on an as-if-converted-to-Common-Stock basis) and in
the same form as dividends actually paid on shares of the common
stock when, as and if such dividends are paid on shares of the
common stock. The Corporation shall pay no dividends on shares of
the common stock unless it simultaneously complies with the
previous sentence.
Voting
Rights: The Series B Convertible Preferred Stock will
vote together with the common stock on an as converted basis
subject to the Beneficial Ownership Limitations (not in excess of
4.99% conversion limitation). However, as long as any shares of
Series B Convertible Preferred Stock are outstanding, the
Corporation shall not, without the affirmative vote of the Holders
of a majority of the then outstanding shares of the Series B
Convertible Preferred Stock directly and/or indirectly (a) alter or
change adversely the powers, preferences or rights given to the
Series B Convertible Preferred Stock or alter or amend this
Certificate of Designation, (b) authorize or create any class of
stock ranking as to redemption or distribution of assets upon a
Liquidation (as defined in Section 5) senior to, or otherwise pari
passu with, the Series B Convertible Preferred Stock or, authorize
or create any class of stock ranking as to dividends senior to, or
otherwise pari passu with, the Series B Convertible Preferred
Stock, (c) amend its Articles of Incorporation or other charter
documents in any manner that adversely affects any rights of the
Holders, (d) increase the number of authorized shares of Series B
Convertible Preferred Stock, or (e) enter into any agreement with
respect to any of the foregoing.
Liquidation: Upon any
liquidation, dissolution or winding-up of the Corporation, whether
voluntary or involuntary (a “Liquidation”), the Holders shall be
entitled to receive out of the assets, whether capital or surplus,
of the Corporation an amount equal to the Stated Value, plus any
accrued and unpaid dividends thereon and any other fees or
liquidated damages then due and owing thereon under this
Certificate of Designation, for each share of Series B Convertible
Preferred Stock before any distribution or payment shall be made to
the holders of any Junior Securities, and if the assets of the
Corporation shall be insufficient to pay in full such amounts, then
the entire assets to be distributed to the Holders shall be ratably
distributed among the Holders in accordance with the respective
amounts that would be payable on such shares if all amounts payable
thereon were paid in full.
Conversion: Each share of
Series B Convertible Preferred Stock shall be convertible, at any
time and from time to time from and after the Original Issue Date
at the option of the Holder thereof, into that number of shares of
common stock (subject to the limitations) determined by dividing
the Stated Value of such share of Series B Convertible Preferred
Stock by the Conversion Price. The Conversion Price for the Series
B Convertible Preferred Stock shall be the amount equal to the
lowest traded price for the Company’s common stock for the fifteen
(15) Trading Days immediately preceding the date of such
conversion. All such foregoing determinations will be appropriately
adjusted for any stock dividend, stock split, stock combination,
reclassification or similar transaction that proportionately
decreases or increases the common stock during such measuring
period. Following an event of default, the Conversion price shall
equal the lower of: (a) the then applicable Conversion Price; or
(b) a price per share equaling 80% of the lowest traded price for
the Company’s common stock during the ten (10) trading days
preceding the relevant Conversion.
Redemption: The
Series B Convertible Preferred Stock may be redeemed by payment of
the stated value thereof, with the following premiums based on the
time of the redemption.
|
· |
115%
of the stated value if the redemption takes place within 90 days of
issuance; |
|
|
|
|
· |
120%
of the stated value if the redemption takes place after 90 days and
within 120 days of issuance |
|
|
|
|
· |
125%
of the stated value if the redemption takes place after 120 days
and within 180 days of issuance; and |
|
|
|
|
· |
each
share of Preferred Stock is redeemed one year from the day of
issuance |
On November 19, 2020, pursuant to the terms of a Securities
Purchase Agreement dated November 16, 2020 (the “SPA”), the
Company entered into a new preferred equity financing agreement
with GHS Investments, LLC (“GHS”) in the amount of up to
$600,000. The SPA provides for GHS’s purchase, from time to time,
of up to 600 shares of the newly-designated Series B Convertible
Preferred Stock. The initial closing under the SPA consisted of 45
shares of Series B Convertible Preferred Stock, stated value $1,200
per share, issued to GHS for an initial purchase price of $45,000,
or $1,000 per share. At the Company’s option, and subject to the
terms of the SPA and the Certificate of Designation for the Series
B Convertible Preferred Stock (the “COD”), additional
closings in the amount of 40 shares of Series B Convertible
Preferred Stock for a total purchase price of $40,000 may take
place at a rate of up to once every 30 days. In connection with the
initial closing in the amount of 45 shares of Series B Convertible
Preferred Stock, the Company issued an additional 25 shares of
Series B Convertible Preferred Stock to GHS as a service fee.
On November 19, 2020 (the date of receipt of cash proceeds of
$45,000 issuance), the Company
valued the fair value of the derivative and recorded an initial
derivative liability of $103,267, $58,267 as day one loss on the
derivative, $39,000 as interest expense, and
$39,000 as Series B Convertible
Preferred Stock mezzanine liability, and $84,000 as
amortization. The Company recalculated the value of the derivative
liability associated with the convertible note and recorded a gain
of $25,701
and a loss of $7,755
for the three months ended September 30, 2022 and 2021,
respectively, and recorded a gain of $28,848
and a gain of $79,211
for the nine months ended September 30, 2022 and 2021,
respectively, in connection with the change in fair market value of
the derivative liability. In addition, the Company recorded
$2,541 and $2,541 as preferred stock dividend
for the three months ended September 30, 2022 and 2021, and
$7,539 and $7,539 for the nine months ended
September 30, 2022 and 2021, respectively, payable to GHS.
Preferred stock dividend payable to GHS was $18,779 and $11,240 as of September 30, 2022
and December 31, 2021, respectively.
On December 16, 2020, pursuant to the terms of the SPA, GHS
purchased an additional 85 shares of Series B Convertible Preferred
Stock for gross proceeds of $85,000. The Company paid $1,700
in selling commissions to complete this financing.
On December 16, 2020 (the date of receipt of cash proceeds of
$85,000 issuance), the Company
valued the fair value of the derivative and recorded an initial
derivative liability of $106,241, $1,700 as interest expense,
$102,000 as Series B Convertible
Preferred Stock a mezzanine liability, and $102,000 as
amortization. The Company recalculated the value of the derivative
liability associated with the convertible note and recorded a gain
of $31,208
and a loss of $10,348 for the three months
ended September 30, 2022 and 2021, respectively, and recorded a
gain of $40,096
and $93,358
for the nine months ended September 30, 2022 and 2021,
respectively, in connection with the change in fair market value of
the derivative liability. In addition, the Company recorded
$3,085 and $3,085 as preferred stock dividend
for the three months ended September 30, 2022 and 2021, and
$9,155 and $9,155 for the nine months ended
September 30, 2022 and 2021, respectively, payable to GHS.
Preferred stock dividend payable to GHS was $21,898 and $12,743 as of September 30, 2022
and December 31, 2021, respectively.
On February 7, 2022 (the date of receipt of cash proceeds of
$51,000 issuance), the Company
valued the fair value of the derivative and recorded an initial
derivative liability of $65,025, $15,025 as day one loss on the
derivative, $10,200 as interest expense, and
$10,200 as Series B Convertible
Preferred Stock mezzanine liability, and $61,200 as
amortization. The Company recalculated the value of the derivative
liability associated with the convertible note and recorded a gain
of $18,725
for the three months ended September 30, 2022, and a gain of
$17,667
for the nine months ended September 30, 2022, in connection with
the change in fair market value of the derivative liability. In
addition, the Company recorded $1,851 as preferred stock dividend
for the three months ended September 30, 2022, and $4,728 as preferred dividend for the
nine months ended September 30, 2022, payable to GHS. Preferred
stock dividend payable to GHS was $4,728 as of September 30,
2022.
On March 24, 2022 (the date of receipt of cash proceeds of
$136,000 issuance), the Company
valued the fair value of the derivative and recorded an initial
derivative liability of $328,422, $192,422 as day one loss on
the derivative, $27,200 as interest expense, and
$27,200 as Series B Convertible
Preferred Stock mezzanine liability, and $163,200 as
amortization. The Company recalculated the value of the derivative
liability associated with the convertible note and recorded a gain
of $49,934
and $190,813
for the three months and nine months ended September 30, 2022, in
connection with the change in fair market value of the derivative
liability. In addition, the Company recorded preferred stock
dividend of $4,936 and $10,194 for the three months and
nine months ended September 30, 2022 payable to GHS. Preferred
stock dividend payable to GHS was $10,194 as of September 30,
2022.
The Company valued the fair value using the Black-Scholes option
pricing model at September 30, 2022, with the following
assumptions: conversion exercise price - $0.0031, the closing stock price of
the Company's common stock on the date of valuation - $0.0032, an expected dividend yield -
0%, expected volatility –
177.44%, risk-free interest rate
– 4.05%, and an expected term
– 1.5 years.
As a result of receipt of cash proceeds relating to Series B
Convertible Preferred Stock, the Company recorded derivative
liability of $328,839 and $212,816 at September 30, 2022
and December 31, 2021, respectively. In addition, preferred stock
dividend payable was $55,600 and $23,983 at September 30,
2022 and December 31, 2021, respectively, and loss on derivatives
for the three months and nine months ended September 30, 2022 was
$5,504 and $207,447, and for the
three months and nine months ended September 30, 2021 was
$0 and $0, respectively.
Warrants
A summary of the status of the Company’s warrants as of September
30, 2022 and 2021, and changes during the three months then
ended, is presented below:
Summary of warrant activity |
|
|
|
|
|
|
|
|
|
|
|
Shares Under Warrants |
|
|
Weighted Average Exercise Price |
|
|
Weighted Average Remaining Contractual Life |
|
Outstanding at December 31, 2020 |
|
|
– |
|
|
|
– |
|
|
|
|
|
Issued |
|
|
2,868,397 |
|
|
$ |
0.00084 |
|
|
|
3.4
Years |
|
Exercised |
|
|
– |
|
|
|
– |
|
|
|
|
|
Expired/Forfeited |
|
|
– |
|
|
|
– |
|
|
|
|
|
Outstanding at September 30,
2021 |
|
|
2,868,397 |
|
|
$ |
0.00084 |
|
|
|
2.7
Years |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at December 31, 2021 |
|
|
– |
|
|
|
– |
|
|
|
|
|
Issued |
|
|
2,868,397 |
|
|
$ |
0.00084 |
|
|
|
2.4
Years |
|
Exercised |
|
|
– |
|
|
|
– |
|
|
|
|
|
Expired/Forfeited |
|
|
– |
|
|
|
– |
|
|
|
|
|
Outstanding at September 30,
2022 |
|
|
2,868,397 |
|
|
$ |
0.00084 |
|
|
|
1.7
Years |
|
NOTE 10 - SUBSEQUENT
EVENTS
Management has evaluated subsequent events through the date of this
Report, the date the financial statements were available to be
issued, noting the following items that would impact the accounting
for events or transactions in the current period or require
additional disclosure.
On October 16, 2022, pursuant to the Equity Financing Agreement,
the Company sold 6,130,677 shares of its common stock for cash
consideration of $12,038 and paid sales commissions of $241.
On November 1, 2022, pursuant to the Equity Financing Agreement,
the Company sold 6,364,961 shares of its common stock for cash
consideration of $10,936 and paid sales commissions of $219.
Item 2.
Management’s Discussion and Analysis of Financial Condition and
Results of Operations
This Management’s Discussion and Analysis of Financial Condition
and Results of Operations contain certain forward-looking
statements. Historical results may not indicate future performance.
Our forward-looking statements reflect our current views about
future events; are based on assumptions and are subject to known
and unknown risks and uncertainties that could cause actual results
to differ materially from those contemplated by these statements.
Factors that may cause differences between actual results and those
contemplated by forward-looking statements include, but are not
limited to, those discussed in the “Risk Factors” section of our
Annual Report on Form 10-K for the year ended December 31, 2021. We
undertake no obligation to publicly update or revise any
forward-looking statements, including any changes that might result
from any facts, events, or circumstances after the date hereof that
may bear upon forward-looking statements. Furthermore, we cannot
guarantee future results, events, levels of activity, performance,
or achievements
Basis of Presentation
The financial information presented below and the following
Management Discussion and Analysis of the Consolidated Financial
Condition, Results of Operations, Stockholders’ Equity and Cash
Flow for the quarterly periods ended September 30, 2021 and 2022
gives effect to our acquisition of OXYS Corporation (“OXYS”)
on July 28, 2017. In accordance with the accounting reporting
requirements for the recapitalization related to the “reverse
merger” of OXYS, the financial statements for OXYS have been
adjusted to reflect the change in the shares outstanding and the
par value of the common stock of OXYS. Additionally, all
intercompany transactions between the Company and OXYS have been
eliminated.
Forward-Looking Statements
Statements in this management’s discussion and analysis of
financial condition and results of operations contain certain
forward-looking statements. To the extent that such statements are
not recitations of historical fact, such statements constitute
forward looking statements which, by definition involve risks and
uncertainties. Where in any forward-looking statements, if we
express an expectation or belief as to future results or events,
such expectation or belief is expressed in good faith and believed
to have a reasonable basis, but there can be no assurance that the
statement of expectation or belief will result or be achieved or
accomplished.
Factors that may cause differences between actual results and those
contemplated by forward-looking statements include those discussed
in “Risk Factors” and are not limited to the following:
|
· |
the
unprecedented impact of COVID-19 pandemic on our business,
customers, employees, subcontractors and supply chain, consultants,
service providers, stockholders, investors and other
stakeholders; |
|
· |
the
impact of conflict between the Russian Federation and Ukraine on
our operations; |
|
· |
geo-political events, such as the crisis in
Ukraine, government responses to such events and the related impact
on the economy both nationally and internationally; |
|
· |
general market and economic
conditions; |
|
· |
our
ability to maintain and grow our business with our current
customers; |
|
· |
our
ability to meet the volume and service requirements of our
customers; |
|
· |
industry consolidation, including acquisitions by
us or our competitors; |
|
· |
capacity utilization and the efficiency of
manufacturing operations; |
|
· |
success in developing new products; |
|
· |
timing of our new product
introductions; |
|
· |
new
product introductions by competitors; |
|
· |
the
ability of competitors to more fully leverage low-cost geographies
for manufacturing or distribution; |
|
· |
product pricing, including the impact of currency
exchange rates; |
|
· |
effectiveness of sales and marketing resources
and strategies; |
|
· |
adequate manufacturing capacity and supply of
components and materials; |
|
· |
strategic relationships with our
suppliers; |
|
· |
product quality and performance; |
|
· |
protection of our products and brand by effective
use of intellectual property laws; |
|
· |
the
financial strength of our competitors; |
|
· |
the
outcome of any future litigation or commercial dispute; |
|
· |
barriers to entry imposed by competitors with
significant market power in new markets; |
|
· |
government actions throughout the world;
and |
|
· |
our
ability to service secured debt, when due. |
You should not rely on forward-looking statements in this document.
This management’s discussion contains forward looking statements
that involve risks and uncertainties. We use words such as
“anticipates,” “believes,” “plans,” “expects,” “future,” “intends,”
and similar expressions to identify these forward-looking
statements. Prospective investors should not place undue reliance
on these statements, which apply only as of the date of this
document. Our actual results could differ materially from those
anticipated in these forward-looking statements.
Critical Accounting Policies
The following discussions are based upon our financial statements,
which have been prepared in accordance with accounting principles
generally accepted in the United States. These financial statements
and accompanying notes have been prepared in accordance with
accounting principles generally accepted in the United States.
The preparation of these financial statements requires management
to make estimates, judgments and assumptions that affect the
reported amounts of assets, liabilities, revenues and expenses, and
related disclosures of contingencies. We continually evaluate the
accounting policies and estimates used to prepare the financial
statements. We base our estimates on historical experiences and
assumptions believed to be reasonable under current facts and
circumstances. Actual amounts and results could differ from these
estimates made by management.
Trends and Uncertainties
On July 28, 2017, we closed the reverse acquisition transaction
under the Securities Exchange Agreement dated March 16, 2017, as
reported in our Current Report on Form 8-K filed with the
Commission on August 3, 2017. Following the closing, our business
has been that of OXYS, Inc. and HereLab, Inc., our wholly owned
subsidiaries. Our operations have varied significantly following
the closing since, prior to that time, we were an inactive shell
company.
Impact of COVID-19
During the year 2020, the effects of a new coronavirus
(“COVID-19”) and related actions to attempt to control its
spread began to impact our business. The impact of COVID-19 on our
operating results for the year ended December 31, 2021 was limited,
in all material respects, due to the government mandated numerous
measures, including closures of businesses, limitations on
movements of individuals and goods, and the imposition of other
restrictive measures, in its efforts to mitigate the spread of
COVID-19 within the country.
On March 11, 2020, the World Health Organization designated
COVID-19 as a global pandemic. Governments around the world have
mandated, and continue to introduce, orders to slow the
transmission of the virus, including but not limited to
shelter-in-place orders, quarantines, significant restrictions on
travel, as well as work restrictions that prohibit many employees
from going to work. Uncertainty with respect to the economic
effects of the pandemic has introduced significant volatility in
the financial markets.
Historical Background
We were incorporated in the State of New Jersey on October 1, 2003
under the name of Creative Beauty Supply of New Jersey Corporation
and subsequently changed our name to Gotham Capital Holdings, Inc.
on May 18, 2015. We commenced operations in the beauty supply
industry as of January 1, 2004. On November 30, 2007, our Board of
Directors approved a plan to dispose of our wholesale and retail
beauty supply business. From January 1, 2009 until July 28, 2017,
we had no operations and were a shell company.
On March 16, 2017, our Board of Directors adopted resolutions,
which were approved by shareholders holding a majority of our
outstanding shares, to change our name to “IIOT-OXYS, Inc.”, to
authorize a change of domicile from New Jersey to Nevada, to
authorize a 2017 Stock Awards Plan, and to approve the Securities
Exchange Agreement (the “OXYS SEA”) between the Company and
OXYS Corporation (“OXYS”), a Nevada corporation incorporated
on August 4, 2016.
Under the terms of the OXYS SEA, we acquired 100% of the issued
voting shares of OXYS in exchange for 34,687,244 shares of our
Common Stock. We also cancelled 1,500,000 outstanding shares of our
Common Stock and changed our management to Mr. DiBiase who also
served in management of OXYS. Also, one of our principal
shareholders entered into a consulting agreement with OXYS to
provide consulting services during the transition. The OXYS SEA was
effective on July 28, 2017, and our name was changed to “IIOT-OXYS,
Inc.” at that time. Effective October 26, 2017, our domicile was
changed from New Jersey to Nevada.
On December 14, 2017, we entered into a Share Exchange Agreement
(the “HereLab SEA”) with HereLab, Inc., a Delaware
corporation (“HereLab”), and HereLab’s two shareholders
pursuant to which we would acquire all the issued and outstanding
shares of HereLab in exchange for the issuance of 1,650,000 shares
of our Common Stock, on a pro rata basis, to HereLab’s two
shareholders. The closing of the transaction occurred on January
11, 2018 and HereLab became our wholly-owned subsidiary.
At the present time, we have two, wholly-owned subsidiaries which
are OXYS Corporation and HereLab, Inc., through which our
operations are conducted.
General Overview
IIOT-OXYS, Inc., a Nevada corporation (the “Company”), and
OXYS, were originally established for the purposes of designing,
building, testing, and selling Edge Computing systems for the
Industrial Internet. Both companies were, and presently
are, early-stage technology startups that are largely pre-revenue
in their development phase. HereLab is also an
early-stage technology development company. We received our first
revenues in the last quarter of 2017, continued to realize revenues
until 2020 when the pandemic hit, and we realized nominal revenues
through 2021.
We develop hardware, software and algorithms that monitor, measure
and predict conditions for energy, structural, agricultural and
medical applications. We use domain-specific Artificial
Intelligence to solve industrial and environmental challenges. Our
engineered solutions focus on common sense approaches to machine
learning, algorithm development and hardware and software
products.
We use off the shelf components, with reconfigurable hardware
architecture that adapts to a wide range of customer needs and
applications. We use open-source software tools, while still
creating proprietary content for customers, thereby reducing
software development time and cost. The software works with the
hardware to collect data from the equipment or structure that is
being monitored.
We focus on developing insights. We develop algorithms that help
our customers create insights from vast data streams. The data
collected is analyzed and reports are created for the customer.
From these insights, the customer can act to improve their process,
product or structure.
Results of Operations for the Three Months Ended September
30, 2022 Compared to the Three Months Ended September 30,
2021
The Company reported $23,003 and $5,280 in service revenues with
cost of sales of $5,140 and $1,275 for the three months ended
September 30, 2022 and 2021, respectively.
The Company incurred general and administrative expenses
(“G&A”) of $158,818 for the three months ended September
30, 2022 as compared to $208,531 for the same comparable period in
2021. The net decrease of $49,713 in G&A expenses resulted
primarily due to a reduction in professional fees paid to
consultants of $40,778 and reduction in payroll and stock
compensation earned by the Officers and Director of $2,946. The
Company recorded a gain of $125,568 due to the change in the fair
market value of derivative liabilities during the three months
ended September 30, 2022 as compared to a loss of $18,103 for the
same comparable period in 2021. The Company recorded interest
income of $5,986 for the three months ended September 30, 2022 due
to the unsecured promissory note extended to a third party earning
10% interest per annum compared to $0 interest earned in the
comparable period of 2021. The Company recorded an interest expense
of $14,913 for the three months ended September 30, 2022 as
compared to $100,701 for the same comparable period in 2021. The
interest expense decreased because the Company did not record any
amortization of debt discount during the three months ended
September 30, 2022 as compared to recording $82,329 in amortization
of debt discounts to interest expense during the three months ended
September 30, 2021.
Results of Operations for the Nine Months Ended September 30,
2022 Compared to the Nine Months Ended September 30,
2021
The Company recorded $39,503 and $5,280 of revenues and $5,650 and
$1,275 in cost of sales during the nine months ended September 30,
2022 and 2021, respectively.
The Company incurred general and administrative expenses
(“G&A”) of $543,449 for the nine months ended September
30, 2022 as compared to $737,746 for the same comparable period in
2021. The decrease in G&A expenses resulted primarily due to
reduction in professional and consulting fees of $316,400 in the
nine months ended September 30, 2022 as compared to the same
comparable period in 2021. This reduction of expense was offset by
an increase in payroll costs of $99,723 during the nine months
ended September 30, 2022 as compared to the same comparable period
in 2021. The Company recorded a gain of $277,424 due to the change
in the fair market value of derivative liabilities during the nine
months ended September 30, 2022 as compared to a gain of $172,558
for the same comparable period in 2021. The Company recorded a loss
on derivatives of $207,447 and $0 for the nine months ended
September 30, 2022 and 2021, respectively, due to the change in
mark to market of the fair value of derivative liabilities. In
addition, the Company recorded a gain of $120,000 on the
extinguishment of debt upon agreeing with the note holders to a
reduction in the debt conversion price during the nine months ended
September 30, 2021, whereas, no such gain or loss was recorded for
the same comparable period in 2022. The Company recorded an
interest income of $11,647 for the nine months ended September 30,
2022 as compared to $0 for the same comparable period in 2021. The
Company recorded interest expense of $278,605 and $333,039 for the
nine months ended September 30, 2022 and 2021, respectively. The
interest expense decreased due to the Company recording reduction
in the fair market value of the derivative liability to interest
expense. As a result, the Company recorded a loss of $775,217 for
the nine months ended September 30, 2022 as compared to a loss of
$818,211 for the same comparable period in 2021.
Our revenue for the quarter ended September 30, 2022 exceeded the
total revenue for 2021, as was anticipated in our Quarterly Report
on Form 10-Q for the first quarter of 2022.
We continue to gain traction with strategic partners, customers,
and potential customers in our key two markets: Smart Manufacturing
/ Industry 4.0 and Structural Health Monitoring (SHM). These are
both high growth markets. Market research shows the worldwide
Industry 4.0 market in 2021 was $64.9 billion USD and is projected
to be $165.5 billion USD by 2026 (20.6% CAGR).[1]
Also, the worldwide Structural Health Monitoring industry was $2.0
billion USD in 2021 and will reach $4.0 billion USD by 2027 (CAGR
of 14.6%).[2]
Through our collaborations with Aretas Sensor Networks, we have
access to a third market, Indoor Air Quality Monitors, which is
estimated at $3.7 billion USD in 2020 and projected to reach $6.4
billion USD in 2027, growing at 8.2% CAGR.[3]
Year to Date Accomplishments in 2022:
|
· |
We
announced in the first quarter that we entered into an NDA with an
EU Electrical Technology Original Equipment Manufacturer.
Collaborative discussions continue and we expect this agreement to
lead to new business in due time. |
|
|
|
|
· |
The
Canadian Indoor Air Quality Sensor and IIoT Platform company,
Aretas Sensor Networks, with whom we entered into an NDA in the
first quarter, continues to progress as well. In addition to the
initial collaborative agreement signed in the first quarter, we
signed an algorithm development contract in the second quarter and
recorded revenue from that contract in this quarter. We also signed
a co-marketing and co-selling agreement with Aretas in this quarter
and expect revenue from sales commissions in the fourth
quarter. |
|
|
|
|
· |
Our
Structural Health Monitoring business continues to gather momentum,
receiving a contract extension with a New England State’s DOT for
Bridge Monitoring announced in the first quarter for monitoring
throughout the second quarter. A proposal for monitoring and
equipment upgrades for the 2022 to 2023 fiscal year was submitted
in the second quarter and received the formal contract in the third
quarter of 2022. We have recorded revenue on this contract since
July and will continue to receive revenue from the contract through
June of 2023. |
|
|
|
|
· |
We
continue to secure significant and supportive funding. |
|
|
|
|
· |
Our
full time Machine Learning Engineer, hired in the first quarter,
continues to expand our focus on the Artificial Intelligence (AI)
and Machine Learning (ML) aspects of our business |
|
|
|
|
· |
Our
CEO, Cliff Emmons, and COO, Karen McNemar, both renewed their
employment contracts in June, ensuring stable experienced
leadership focused on long-term growth. |
_________________________
[1]
https://www.marketsandmarkets.com/Market-Reports/industry-4-market-102536746.html
[2]
https://www.marketsandmarkets.com/Market-Reports/structural-health-monitoring-market-101431220.html
[3]
https://www.reportlinker.com/p05957040/Global-Indoor-Air-Quality-Monitors-Industry.html
We believe the underlying strengths of the Company are gathering
momentum for expected growth: an experienced leadership team;
contributions of our new Machine Learning Engineer, a PhD level
Machine Learning Algorithms specialist; strong execution on
contracts to date; and a steady focus on prospecting, submitting
proposals, and securing Proof of Concepts (POCs). Those
completed contracts to date have produced two successful pilot
programs: one on manufacturing operations for our Fortune 500
Pharma customer, and a pilot with a full year of data collection
and analysis on our structural health monitoring program for a New
England state’s DOT – which has now led to a bridge monitoring
contract extension, which includes equipment upgrades and
additional analysis. Our continued focus on high potential growth
markets (specifically Biotech, Pharma, and Medical Device
Operations, Structural Health Monitoring, and Indoor Air Quality),
has yielded numerous prospects for future growth. Specifically, we
secured an AI – Machine Learning sub-contract and initiated a POC
for our IAQ strategic partner in the second quarter and signed a
co-marketing and co-selling agreement with the same strategic
partner in the third quarter.
We are pleased that the momentum of the second quarter’s revenue
continued into the third quarter and expect it will continue
through the fourth quarter. Our third quarter revenue exceeded our
second quarter revenue and expect revenue for the second half of
2022 will exceed that generated in the first half of 2022. In
total, we expect that total revenue for 2022 will be approaching
2019 levels. This is due to the hard work of the past year that has
resulted in two successful pilots, in two of our key target
industry verticals. We now have data and algorithms to build strong
use cases and marketing collateral that can be leveraged to extend
contracts with current customers and win additional contracts with
new customers in all targeted industry segments. Also, the strength
of the collaboration agreements with both Aingura IIoT, S.G. and
Aretas Sensor Networks have substantially bolstered financial
stability, added talent breadth and depth, and complimentary
industry segment experience. Furthermore, the continued liquidity
of our stock has attracted funding opportunities, and access to
additional capital has and will enable funding of business
development, intellectual property development, staff augmentation,
and inorganic growth opportunities. Combined with our underlying
strengths: experienced leadership; savvy technological talent, and
operational execution excellence; we believe these revenue goals
are achievable.
As of September 30, 2022, the total principal amount owed to Sergey
Gogin was $205,000. For more information on the note, please see
NOTE 6 - CONVERTIBLE NOTES PAYABLE of the footnotes to the
consolidated, unaudited financial statements.
Liquidity and Capital Resources
At September 30, 2022, the Company had a cash balance of $34,284,
which represents a $12,537 reduction from the $46,821 balance at
December 31, 2021. This reduction was primarily the result of cash
provided by the sale of common stock of $481,657 and Series B
preferred stock (net of offering costs of $9,633) in the aggregate
amount of $187,000, offset by net cash used in operating activities
of $471,561 due to acceleration in product development activities,
and cash used in investing activities by executing a note
receivable of $200,000 from Aretas. The Company’s working capital
at September 30, 2022 was a deficit of $1,473,996, as compared to a
working capital deficit of $1,108,786 at December 31, 2021.
The accompanying financial statements have been prepared assuming
the Company will continue as a going concern. As shown in the
accompanying financial statements, the Company has incurred losses
from operations of $775,217 for the nine months ended September 30,
2022, and has an accumulated deficit of $9,005,473 at September 30,
2022, which raises substantial doubt about the Company’s ability to
continue as a going concern.
Management believes the Company will continue to incur losses and
negative cash flows from operating activities for the foreseeable
future and will need additional equity or debt financing to sustain
its operations until it can achieve profitability and positive cash
flows, if ever. Management plans to seek additional debt and/or
equity financing for the Company but cannot assure that such
financing will be available on acceptable terms. At the Company’s
current rate of expenditure, the Company anticipates being able to
maintain current operations for three months; however, management
is proposing to raise any necessary additional funds not provided
by operations through loans or through additional sales of equity
securities. There is no assurance that the Company will be
successful in raising this additional capital or in achieving
profitable operations.
The Company’s continuation as a going concern is dependent upon its
ability to ultimately attain profitable operations, generate
sufficient cash flow to meet its obligations, and obtain additional
financing as may be required. Our auditors have included a going
concern qualification in their auditors’ report dated April 14,
2022. Such a going concern qualification may make it more difficult
for us to raise funds when needed. The outcome of this uncertainty
cannot be assured.
The accompanying financial statements do not include any
adjustments that might result from the outcome of this uncertainty.
There can be no assurance that management will be successful in
implementing its business plan or that the successful
implementation of such business plan will actually improve the
Company’s operating results.
Recently Issued Accounting Standards
Management does not believe that any other recently issued, but not
yet effective, accounting standards if currently adopted would have
a material effect on the accompanying financial statements.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that have or are
reasonably likely to have a current or future material effect on
our consolidated financial condition, changes in financial
condition, revenues or expenses, results of operations, liquidity
capital expenditures or capital resources.
Emerging Growth Company
We are an “emerging growth company,” as defined in the Jumpstart
Our Business Startups Act of 2012, or the JOBS Act. Certain
specified reduced reporting and other regulatory requirements that
are available to public companies that are emerging growth
companies. These provisions include:
|
1. |
an
exemption from the auditor attestation requirement in the
assessment of our internal controls over financial reporting
required by Section 404 of the Sarbanes-Oxley Act of
2002; |
|
2. |
an
exemption from the adoption of new or revised financial accounting
standards until they would apply to private companies; |
|
3. |
an
exemption from compliance with any new requirements adopted by the
Public Company Accounting Oversight Board, or the PCAOB, requiring
mandatory audit firm rotation or a supplement to the auditor’s
report in which the auditor would be required to provide additional
information about our audit and our financial statements;
and |
|
4. |
reduced disclosure about our executive
compensation arrangements. |
We have elected to take advantage of the exemption from the
adoption of new or revised financial accounting standards until
they would apply to private companies. As a result of this
election, our financial statements may not be comparable to public
companies required to adopt these new requirements.
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
As a smaller reporting company, the Company has elected not to
provide the disclosure required by this item.
Item 4. Controls
and Procedures
Disclosure Controls and Procedures
The Company has established disclosure controls and procedures that
are designed to ensure that information required to be disclosed in
reports filed or submitted under the Securities Exchange Act of
1934, as amended (the “Exchange Act”), is recorded,
processed, summarized and reported within the time periods
specified in the rules and forms of the Securities and Exchange
Commission and, as such, is accumulated and communicated to the
Company’s Chief Executive Officer, Clifford L. Emmons, who serves
as our principal executive officer, and to the Company’s Interim
Chief Financial Officer, Karen McNemar, who serves as our principal
financial and accounting officer, as appropriate to allow timely
decisions regarding required disclosure. Mr. Emmons and Ms.
McNemar, evaluated the effectiveness of the Company’s disclosure
controls and procedures, as defined in Rule 13a-15(e) of the
Exchange Act, as of September 30, 2022. Based on their evaluation,
Mr. Emmons and Ms. McNemar concluded that the Company’s disclosure
controls and procedures were not effective as of September 30,
2022.
Changes in Internal Control Over Financial
Reporting
There has been no change in the Company’s internal control over
financial reporting, as defined in Rules 13a-15(f) of the Exchange
Act, during the Company’s quarter ended September 30, 2022, that
has materially affected, or is reasonably likely to materially
affect, the Company’s internal control over financial
reporting.
PART II—OTHER
INFORMATION
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
Equity Financing Agreement
On November 1, 2021, we entered into an Equity Financing Agreement
with GHS Investments, LLC (“GHS”) for an equity line.
Although we are not required to sell shares under the Equity
Financing Agreement, the Equity Financing Agreement gives us the
option to sell to GHS up to $2,500,000 worth of our common stock,
in increments, beginning on the first trading day after the
effective date of this Registration Statement and ending on the
earlier of (i) the date GHS has purchased an aggregate of
$2,500,000 of our common stock pursuant to the Equity Financing
Agreement, (ii) November 1, 2023, twenty-four months from the date
of execution of the Equity Financing Agreement, or (iii) upon
mutual termination of the Equity Financing Agreement (the “Open
Period”).
During the Open Period, we may, in our sole discretion, deliver a
put notice (“Put Notice”) to GHS which shall state the
dollar amount requested by us (the “Put Amount”) and number
of shares intends to sell to GHS on a designated closing date. The
purchase price (the “Purchase Price”) of the common stock
sold pursuant to a Put Notice will be set at 90% of the lowest
volume-weighted average price of our common stock during the ten
consecutive trading day period immediately preceding the date on
which we deliver the Put Notice to GHS. We are obligated to deliver
a number of shares to GHS equal to Put Amount divided by the
Purchase Price in consideration of the payment of the Put
Amount.
Below is a table of all puts made by the Company under the Equity
Financing Agreement during the quarter ended September 30,
2022:
Date of Put |
Number of Shares
Sold |
Total Proceeds, Net of
Discounts |
Effective Price per
Share |
Net Proceeds |
7/28/22 |
2,984,997 |
$12,211 |
$0.004090909 |
$11,967 |
8/15/22 |
3,021,668 |
$10,136 |
$0.0033545 |
$9,933 |
8/30/22 |
5,865,257 |
$20,635 |
$0.0035182 |
$20,222 |
9/15/22 |
5,600,661 |
$17,871 |
$0.0031909 |
$17,513 |
9/30/22 |
10,817,889 |
$27,438 |
$0.0025364 |
$26,889 |
The shares issued in reliance upon the exemption from securities
registration afforded by Section 4(a)(2) of the Securities Act and
Rule 506(b) of Regulation D under the Securities Act, based in part
on the representations of the investor. There were $1,763 in sales
commissions paid to J.H. Darbie & Co., Inc. (“J.H.
Darbie”) pursuant to these transactions.
Item 6.
Exhibits
*Filed with this Report.
**Furnished with this Report.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
|
IIOT-OXYS,
Inc. |
|
|
|
|
|
|
Date: November 14,
2022 |
By |
/s/ Clifford L.
Emmons |
|
|
Clifford L. Emmons, Chief
Executive Officer |
|
|
(Principal Executive
Officer) |
|
|
|
|
|
|
Date: November 14,
2022 |
By |
/s/ Karen
McNemar |
|
|
Karen McNemar, Interim Chief
Financial Officer |
|
|
(Principal Financial and
Accounting Officer) |
IIOT OXYS (PK) (USOTC:ITOX)
Historical Stock Chart
From Jan 2023 to Feb 2023
IIOT OXYS (PK) (USOTC:ITOX)
Historical Stock Chart
From Feb 2022 to Feb 2023